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 Metastasis is the spread of cancer from the site of origin to a distant site, where 
the colony of malignant cells grows. Growth of malignant cells in secondary sites disrupts 
organ function and increases the tumor burden on the host. Thus, there is a critical need 
to understand the factors regulating the spread of cancer cells to distant sites and their 
growth therein. Over half of all patients diagnosed with pancreatic ductal adenocarcinoma 
(PDAC) present with liver metastasis, and five-year survival for these patients is currently 
three percent. We performed an in vivo screen for PDAC metastasis suppressors using 
a human whole-genome shRNA library in order to understand factors regulating PDAC 
metastasis and identified Inter-α-Trypsin Inhibitor Heavy Chain 5 (ITIH5) as a suppressor 
of PDAC metastasis. Knockdown of ITIH5 significantly increased liver metastasis while 
high ITIH5 expression was correlated with rounded cell morphology and decreased cell 
motility and metastasis. ITIH5 is a secreted protein related to plasma protease inhibitors. 
To test the hypothesis that secretion of ITIH5 is required to suppress metastasis, we 
deleted the secretion signal sequence of ITIH5 (ITIH5Δs) and compared development of 
liver metastasis in highly metastatic PDAC cells expressing either control vector, secreted 
ITIH5, or secretion-deficient ITIH5Δs. Intriguingly, ITIH5Δs was sufficient to recapitulate 
the effects of secreted ITIH5 on cell morphology, motility and metastasis. These data 
suggest that ITIH5 may suppress metastasis by an intracellular mechanism not predicted 
by previously published reports. Understanding how intracellular ITIH5 attenuates PDAC 
metastasis could reveal new elements of PDAC biology that could become future 
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 - Introduction 
 
Biology of Metastasis 
Cancer is a disease of intrinsic failed feedback inhibition: whereas normal cells 
respond to many homeostatic controls to keep the organism alive, cancer cells have lost 
this priority, grow unchecked and prioritize their own survival above all else. The spread 
of cancer cells to distant sites is called metastasis, which comes from the Greek word 
methistanai, which refers to a change in place, standing or position (meta “change”, 
histanai “to (cause to) stand, to place”). Metastasis is a particularly fearsome attribute of 
malignant cells because this spread can disrupt the function of otherwise uninvolved 
organs. Simultaneously, metastasis undermines the physician’s ability to treat the cancer 
as a local disease and the patient’s ability to regard it as such. Patients with metastatic 
cancer generally have a worse prognosis than patients with localized disease [1]. Thus, 
there is a critical need to understand metastasis so that therapeutic strategies can be 
developed to curb the spread of a patient’s cancer and the toll the disease exacts from 
its host. Here, we will explore the biology of metastasis, tools for measuring this process 
and highlight pancreatic cancer as an example of how metastasis suppressors, genes 
that suppress metastasis without necessarily suppressing primary tumor growth [2], can 
be identified and studied to understand how they work to suppress metastasis in a cancer 
for which this spread occurs early, frequently and contributes to a poor patient prognosis.    
While cancer may not obey the decreed guidelines for physiologic homeostasis, it 
is still constrained by the laws that govern all of biology such as the implications of 
thermodynamics for energy metabolism, membrane enclosed cells being the fundamental 
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system units, and selection on variation driving change in a population [3].  These 
constraints have implications for how cancer starts, evolves, spreads and is treated. 
Cancer appropriates processes from normal cell biology for its own survival. The cellular 
tools (e.g. proteins) used by cancer cells to perform a task like migration are the same 
tools used for migration in normal physiology. This then, may prove to be a double-edged 
sword—perhaps normal biology might be used as a platform for understanding the 
functions of these genes, transcripts and proteins co-opted by cancer for growth and 
metastasis. Next, we will explore the parallels between metastatic cancer cells and 
normal cells that use the same “tools”, such as stem cells and so-called cancer stem cells. 
The goal is to draw out and understand themes that may be leveraged to understand the 
biology of metastasis and design rational future therapeutic strategies.  
Parallels drawn between stem cells and cancer are not new [4] i. However, these 
shared features are becoming increasingly important as our understanding of 
disseminated, recurrent and metastatic cancer cell biology continues to develop. Indeed, 
nearly all cancer-related deaths are the result of recurrent and metastatic disease, 
highlighting the need for a more comprehensive schema of how tumors colonize new 
sites, resist therapy and evolve. In this chapter, we compare the phenotypes of stem cells, 
cancer stem cells (CSCs) and metastatic cells, highlighting notable points of contrast. We 
begin with an introduction to stem cell biology, tumor initiating CSCs, metastatic cells and 
discuss shared features. The implication of the stem-like phenotype extends to many 
                                            
i The following four paragraphs previously appeared in Chapter 1 of Cancer Metastasis and 
Cancer Stem Cell/Niche, “Fundamental Relationships Between Cancer Stem Cells, the Cancer Stem Cell 
Niche and Metastasis.” Pp. 3-23 (21), DOI: 10.2174/97816810834761160101. It has been updated here. 




characteristics of cell biology: cell division, differentiation, morphology, gene expression, 
motility, invasion, clonogenicity, capacity for colonization, metabolism and the interaction 
of these cells with their surrounding microenvironment. Stem cell phenotypes are highly 
complex and, while there may be a number of shared features, there are important 
elements that are uniquely tissue-dependent. While staunch definitions based upon a 
single biomarker of stemness have proven inadequate in broader applications, identifying 
universal themes of the stem cell phenotype may provide critical insights for studying 
cancer. Our understanding of this complex biology is critical for developing rational and 
dynamic therapeutic interventions for patients with recurrent and metastatic cancer. 
The observation that features of a cancer cell resemble developmentally primitive 
cells dates back over 150 years [5]. This has proven to be a perspicacious observation 
indeed, given the similarities between cancer cells and stem cells with respect to their 
dynamic regulation of mitosis, gene expression, migration, metabolism and self-
preservation. Cell division is a critical component of carcinogenesis and early 
observations prompted the notion that cancer may arise from a stem cell [6, 7]. 
Additionally, the therapeutic significance of cancer cells displaying a stem cell-like 
phenotype has been more recently appreciated after patients whose cancer was treated 
with chemotherapy and were without evidence of disease, experienced recurrence of 
disease months or years later. These observations suggested that there was perhaps a 
population of mitotically quiescent cancer cells unaffected by chemotherapy that survived, 
proliferated and gave rise to the recurrent tumor or metastatic disease [8]. Tumor-initiating 
cells are the proposed “cancer stem cells” (CSCs). Given the importance of these 
phenotypes in the control of cancer, here we compare the shared and distinct biological 
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features of normal stem cells, CSCs and metastatic cancer cells and consider the 
therapeutic significance of these insights. 
Stem cells are populations of cells with the capacity to divide symmetrically, where 
the resulting daughter cells retain an equal potential to produce cells of a given lineage, 
or asymmetrically, resulting in more differentiated daughter cells that are narrowed in the 
variety of cells in that lineage they can produce [9]. It was thought that stem cells spend 
the majority of their cell cycle in vivo in mitotic quiescence [10], and upon stimulation by 
tissue damage or exogenous factors they can be induced to divide. More recently, in 
addition to quiescent stem cells, it has been shown that a population of Lgr5+stem cells 
also undergo active proliferation [11]. Daughter cells resulting from asymmetric divisions 
may become the more actively proliferating yet shorter-lived transit-amplifying cells which 
serve to regenerate tissue when required [12]. When stem cells are cultured in vitro 
however, conventional passaging methods may select for rapidly proliferating cells [13], 
explaining in part the dissonance between these two phenotypes. Ultimately, the 
orchestrated proliferation and differentiation of normal stem cells serve to reconstitute 
tissue lost to damage, aging and use. In a similar way, tumor cells remaining after 
selection by chemotherapy would be the “stem cells” of that tumor. These CSCs could 
eventually be stimulated to divide, resulting in the maintenance of slow-cycling CSCs. 
Stochastic changes in other daughter cells would re-establish tumor heterogeneity and a 







 Metastatic cancer cells are defined by the ability to leave the primary tumor, enter 
and survive in the circulation, arrest at a different site and proliferate there to form a 
metastatic colony [14]. Enhancing any step along this cascade has the potential to 
increase metastatic efficacy, while a deficiency in any step will definitively avert 
metastasis. Metastasis is inefficient; less than one percent of the cells that enter the 
circulation are capable of forming a metastatic colony [15] and if disseminated cells are 
prevented from outgrowth after arriving at the secondary site, they will not form a 
metastatic colony [16]. 
 As we have discussed above, cancer co-opts proto-oncogenes for survival, 
proliferation and migration to survive and spread. Conversely, tumor suppressor genes 
oppose cancer growth and spread. While tumor suppressors may slow both the growth 
of the primary tumor and metastasis, metastasis suppressors resist a cancer’s ability to 
complete the metastatic cascade without necessarily affecting growth of the primary 
tumor [2]. Many metastasis suppressor genes have been identified and have been shown 
to suppress metastasis in multiple tumor types including melanoma [17], breast [18], 
colon [19], squamous cell carcinoma [20], prostate [21], ovarian [22], bladder [23] and 
pancreas [24]. These genes vary widely in their biochemical function and include kinases, 
integrin interacting proteins, chromatin remodeling complex components, neuropeptides, 
transcriptional coactivators and GTPase regulators. The goal of metastasis suppressor 
research is to understand the mechanism of metastasis suppression thoroughly enough 
to create a treatment that mimics the biological effect and effectively suppress human 
metastasis [25]. To date, this hope remains unrealized. 
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 While their biochemical classifications are distinct, metastasis suppressors share 
a common ability to reduce metastasis when expressed. Suppression of metastasis may 
affect any step along the metastatic cascade. By observing the number, size and 
distribution of metastases, we may begin to gain insights into the suppressor’s 
mechanism of action, that is, which step in the metastatic cascade it affects. The first 
metastasis suppressor gene to be identified was NM23 (also called NME1) in murine 
melanoma [26]. Its expression was significantly higher in poorly metastatic cells as 
compared to their highly metastatic counterparts. Other metastasis suppressors, like 
KISS1, reduce the size of the disseminated cancer colonies, suggesting an effect on 
disseminated cell proliferation at the secondary site [27]. Interestingly, while effects of 
KISS1 expression are minimal on the primary tumor, KISS1-expressing cells are 
dramatically suppressed in their ability to colonize multiple organ sites such as the lung, 
bone and kidney [28]. Another metastasis suppressor, Inter-Alpha-Trypsin-Inhibitor 
Heavy Chain 5 (ITIH5), seems to reduce both the size and number of metastases in 
addition to slight reductions in primary tumor growth, suggesting a more intrinsic effect on 
the cancer cells [29]. 
 
Quantification of Metastasis Assays 
  The quantification of metastasis is an important prerequisite for studying and 
understanding this complex process. Early efforts in studying metastasis recognized that 
while the natural history of metastasis involves spontaneous shed of cells from the 
primary tumor that seed a colony at a secondary site, experimentally seeding cancer cells 
into a secondary site by using an intravenous injection increased their ability to regulate 
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the variables of the experiment. In these early experimental metastasis assays, cancer 
cells were injected intravenously into a mouse to seed the first capillary bed they 
contacted, the lung. By using melanoma cells, the melanin produced resulted in black 
cancer cells that were easily visible on the surface of the lung at necropsy and aided in 
visual counting of gross metastases. An important observation regarding metastasis was 
made using these tools: metastatic efficacy is a phenotype that can be change under 
selective pressure, like most other processes in biology [30].  
Methods for quantifying gross metastases in amelanotic cancers employed either 
a biological dye component in Bouin’s fixative [31], India ink [32] or genetically labeled 
fluorescent reporters [33] to provide contrast against the lung tissue and to facilitate 
identification under fluorescent dissecting microscopes.  All of these methods require 
euthanasia of the model animal however, and quantifying metastasis in vivo proved a 
more difficult problem. Luciferase reporters allowed for whole-body imaging of 
experimental animals bearing metastases [34] and provided quantification of tumor 
burden at the expense of resolution. The combination of fluorescent reporters to pre-
existing methods for in vivo microscopy allowed for increased resolution of metastatic 
growth in vivo [35], which allowed for the study of cellular processes already known to be 
involved in metastatic colonization to be visualized in real-time. The development of ex 
vivo tissue culture techniques such as the Pulmonary Metastasis Assay [36] allowed for 
disseminated cancer cells to be grown in living tissue and for the study of factors affecting 
the growth of metastatic cells to be observed directly. Such methods of quantifying lung 
metastases are relevant to many different cancer types including both melanoma [37] and 
pancreatic cancer [38]. 
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A remaining challenge in all of these methods is that the greater the biological 
relevance of a model (e.g. a genetic model that develops spontaneous metastases), the 
more challenging real-time imaging and quantification of those metastases becomes. 
Conversely, models best suited for high resolution imaging of the disseminated metastatic 
cells are often criticized for their lack of biological relevance. Models are generally tailored 
to answer a specific scientific question. Likewise, by definition, a model is intrinsically 
different from the process it is used to study as noted by the twentieth century statistician 
George Box, “All models are wrong, but some are useful” [39]. Thus it seems that the 
progression of models for the study of metastasis has been driven and will continue to be 
guided by the ability of the scientist to use the model to quantify elements of the metastatic 
process and the genetic, pharmacological and optical technologies driving such 
development.  
 
Pancreatic Cancer and Metastasis 
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease. It may have been 
described as early as the 18th century, [40] and has since been more thoroughly defined. 
It remains the fourth leading cause of cancer deaths for men and women [1] and 
unfortunately, a lack of effective treatment strategies is a persistent challenge in PDAC. 
This is illustrated by the fact that despite being the top four leading cause of cancer death, 
the incidence of PDAC does not rank within the top ten cancers diagnosed in men and is 
eighth on the list for women. This is in striking contrast to a disease like melanoma, where 
the incidence is high, ranking fifth in men and sixth in women, yet melanoma fails to 
number among the top ten list of cancers contributing to death. Melanoma primary tumors 
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are accessible to surgical excision, which is effective in reducing or preventing further 
morbidity and mortality to the patient [41]. Furthermore, recent advances in systemic 
therapies, such as immunotherapy, have proven effective in treating disseminated 
melanoma [42]. Patients diagnosed with PDAC do not have such therapeutic advantages, 
which is reflected in the current prognosis of this disease. The overall five-year survival 
for pancreatic cancer is only eight percent. Astoundingly, over half of all patients 
diagnosed with pancreatic cancer (52-56%) are diagnosed with disseminated disease. 
The liver is a common site for metastasis [43] and for these patients, the five-year survival 
is only three percent. Understanding the causes of PDAC tumorigenesis and metastasis 
are critical for the development of effective treatments for this devastating disease.  
Pancreatic cancer is defined by a small number of driver mutations found in the 
vast majority of these tumors: KRAS, p53, p16 and SMAD4 [44]. These same mutations 
have inspired a number of mouse models of pancreatic cancer [45]. While it seems that 
a defined number of mutations define the progress of PDAC tumorigenesis, these same 
driver mutations are retained within the metastases and at present, there are no known 
analogous mutations acting specifically as drivers of metastatic spread of pancreatic 
cancer [46]. One question that arises then, is if genes are not being selected to drive 
metastatic progression, which other transmissible markers of cellular function are? Other 
possible cellular targets include epigenetic modifications to DNA and histones. Epigenetic 
marks such as methylation, acetylation, phosphorylation, ubiquitination and sumoylation 
affect gene expression and are both stable enough to be transmitted for selection [47] 
and have been shown to change during PDAC metastasis [48]. Thus, they represent a 
field ripe for the study of tumor evolution.  
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Epigenetic modifications stably affect gene expression without modification of the 
DNA sequence and are actively regulated during dynamic biological processes such as 
development [49]. Like development, the metastatic cascade requires dramatic changes 
in gene expression and cell behavior. In pancreatic cancer, there is accumulating 
evidence that such changes may indeed be critical for metastatic progression [46, 48, 
50]. Understanding the changes required for metastasis and selected for during 
tumorigenesis are critical for understanding and curbing the spread of pancreatic cancer. 
Currently, two clinical trials aim to detect epigenetic changes in metastatic PDAC [51, 52], 
but neither attempt to therapeutically modulate chromatin regulation.  
 
Inter-alpha-trypsin-inhibitor-heavy chain Family  
In order to identify genes regulating PDAC metastasis to the liver, we performed a 
genome-wide screen in a non-metastatic human PDAC cell line, S2-028 [29]. This screen 
identified two suppressors of pancreatic cancer metastasis: HMP-19, which was validated 
as a suppressor of PDAC metastasis, and Inter-Alpha-Inhibitor-Heavy-Chain 5 (ITIH5). 
The inter-alpha-inhibitor family (IαI) are a family of secreted serine protease inhibitors that 
were discovered serendipitously in 1961 by the Loeb lab in Paris, France while attempting 
to isolate haptoglobin from the plasma [53]. Originally called protein π (pi), it was identified 
that these proteins were different from ceruloplasmin, haptoglobin and α2-macroglobulin. 
IαI proteins contain three main functional domains: vault protein inter-alpha trypsin (VIT) 
domain, Von Willebrand factor type A (VWA) domain and an inter-alpha-trypsin inhibitor 
heavy chain (ITIH) domain, hereafter referred to as the multi-copper oxidase domain 
(MCOD) [54]. The fact that IαI were found by the Loeb group to not contain copper or 
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oxidative activity makes their MCOD domain a potential cause for confusion. However, 
the IαI MCOD domains are similar to the MCOD of ceruloplasmin, the major copper 
carrying protein in the body [55]. It is possible then IαI can indeed bind copper via this 
domain although this has not been definitively demonstrated for ITIH5. 
The IαI have a complex structure and post-translational processing. They are 
composed of a light chain (Bikunin) and two heavy chains (IαI). The light chain is 
transcribed from the Alpha-1 Microglobulin/Bikunin Precursor (AMBP) gene on 
chromosome 9, while the heavy chains ITIH1, ITIH2, ITIH3, ITIH4, and ITIH5 are 
transcribed from the IαI genes on chromosomes 3, 10, 3, 3 and 10 respectively. 
Extracellularly, the light chain and the heavy chain are each proteolytically cleaved before 
being finally covalently linked to chondroitin sulfate or, in the case of the heavy (IαI) 
chains, binding hyaluronic acid (HA) present in the serum or extracellular matrix [56].  
While IαI are structurally similar to serine protease inhibitors, the majority of the 
protease inhibition has been attributed to Bikunin, which in total, only accounts for 
approximately 5% of the protease inhibitory activity present in the serum [56]. In normal 
physiology, ITIH5 is the strongest expressed IαI in the placenta, skin, breast, adipose and 
pancreas [57]. Specifically, ITIH5 is expressed in the pancreatic islets and pancreatic 
ductal epithelium [29]. Interestingly, while ITIH1-4 are robustly expressed in the liver, 
ITIH5 is not, suggesting perhaps a different function compared to other members of this 
family. ITIH5 is the predominant IαI in the skin, and is expressed by dermal fibroblasts 
but not keratinocytes [58]. Its expression increases in inflammatory skin diseases such 
as psoriasis and ITIH5 knockout mice show extreme thinning of the epidermis, suggesting 
a role for ITIH5 in the maintenance of skin homeostasis. 
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A number of remaining questions surround the role of IαI and ITIH5 in normal 
physiology and in cancer. A tumor suppressive role has been attributed to ITIH5 in a 
number of cancer types  including: breast [54, 59, 60], bladder [61], lung [62], tongue [63], 
central nervous system [64], acute myeloid leukemia [65], colon [60], stomach [66], 
pancreas [29] and thyroid [67]. It has been demonstrated that ITIH5 may change the 
epigenetic state and activation of Rho/Rac signaling [68] and gene expression [69], but 






 - Comparative Biology of Metastasis and Development  
 
The Cancer Stem Cell Phenotype ii 
Discussion of CSCs envelops many concepts related to the origin of malignant 
cells, how selective processes change the tumor cell population over time (i.e. tumor 
progression), the ability of cells to successfully colonize new sites (i.e. metastasis), and 
the features of therapy-resistant cancer cells in disease recurrence (summarized in Table 
2-1 and Fig. 2-1). Although a so-called “tumor-initiating cell” may very well fit many of the 
aforementioned criteria, this nomenclature describes many of the later aspects of CSC 
biology without reference necessarily to their origin, with which we begin our discussion.  
Morphologic observations of cancers and embryonic tissues gave rise to the first 
ideas connecting cancer with stem cells. The strikingly heterogeneous composition of 
teratomas, containing teeth, hair, and sundry embryonic tissues led to the hypothesis that 
these tumors may come from a stem cell [70, 71]. Further studies extended this 
observation and demonstrated the stemness of teratoma cells by showing their potential 
to differentiate into a multitude of tissues [72]. Beyond potency, normal stem cells, 
tumorigenic cancer cells and metastatic cells must all have the capacity for continued 
proliferation, from even a single cell [73]. However, it was observed in leukemia that many 
of the cancer cells had a finite ability to self-renew, which incited the search for the tumor-
sustaining CSCs in this disease. Cell surface markers were used to define a 
subpopulation of human CD34+CD38- acute myeloid leukemia (AML) cells capable of 
                                            
ii The following chapter previously appeared in Chapter 1 of Cancer Metastasis and Cancer Stem 
Cell/Niche, “Fundamental Relationships Between Cancer Stem Cells, the Cancer Stem Cell Niche and 




recapitulating an AML phenotype in SCID mice [74]. This subpopulation was less 
differentiated than the other cells and provided evidence that a defined population of 
resident stem cells is responsible for AML. 
Table 2-1: Similarities between Stem Cells, Cancer Stem Cells and Metastatic 
Cellsiii 
                                            
iii While not exhaustive, this table highlights general trends and shared features between normal 
stem cells, cancer stem cells (CSCs) and metastatic cells.  
 Shared Features Distinguishing Features 
 
Mitotic Rate 
Both slow and actively-cycling 
populations exist [10, 75]. 
Slow-cycling CSC populations are 
tumorigenic and can be 
chemotherapy resistant [76]. 
Actively-cycling CSC populations  
drive tumor progression [77]. 
Genomic Intregity 
Normal stem cells maintain their 
genomic integrity. 
CSCs[78] and metastatic cells [79] 
are genetically unstable. 
 
Dormancy/Quiescence Cells may remain dormant or be 
triggered to actively proliferate [10]. 
 
 
Surface Markers Common markers are shared in 
mammary cells [80] and HSCs [74]. 
Stem cell, CSC and metastatic cells 
markers are vary by tissue. Markers 
may also vary within a tissue [81-83]. 
 
EMT Expression of EMT related markers 
can be observed [80, 84, 85]. 
Reversal of EMT (MET) related 
markers facilitates metastatic 
colonization [86, 87]. 
 
Self-Renewal 
Must be able to self-sustain and 
reconstitute the tissue, even from a 




Have the capacity to migrate from 
the original site and colonize a new 
site [88, 89]. 
Motility may or may not correlate 
with metastatic capacity [16, 89]. 
 
Invasiveness Can invade or migrate through 
surrounding tissues [88, 90] 
Invasiveness is necessary but not 
sufficient for metastasis [90, 91]. 
 
Metabolism Generally show increased glycolytic 




Not inherently drug resistant, 
depends upon mitotic rate and 
phenotype. 
Drug resistance does not guarantee 
metastatic potential. 
 
Niche Provides protection, support and 
regulates growth [95, 96]. 
Cancer associated niches do not 
suppress respective cells. Metastatic 






Figure 2-1: Properties of Stem Cells, Cancer Stem Cells and Metastatic Cells 
 
Mitotic Activity 
There is also evidence for a relationship between the state of differentiation and 
tumorigenic capacity in squamous cell carcinomas, where it was demonstrated that poorly 
differentiated cells were the fastest cycling cells in the tumor [75]. As squamous cell 
carcinoma cancer cells differentiated they became less mitotically active and less 
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tumorigenic, suggesting that there was a primordial population of cells responsible for 
persistence of the tumor and that the cancer cells entered mitotic quiescence as they 
differentiated. The net mitotic index of malignant cancer cells is generally constitutively 
high, a feature that has been exploited by conventional chemotherapies for the past 75 
years [98]. Stem cells in the hilum of the ovary have been demonstrated to be both slow-
cycling and prone to tumorigenesis after tumor-suppressor loss [99], suggesting a role for 
these slow-cycling, normal stem cells in the development of ovarian carcinomas. CSCs 
are hypothesized to have a low mitotic rate that aids in rendering them resistant to 
traditional chemotherapeutics targeting rapidly proliferating cells. Supporting this 
hypothesis, a relatively slow-cycling population of CSCs was shown to drive tumor growth 
in glioblastoma [100]. In an intestinal adenoma model, it was demonstrated that Lgr5+ 
stem cells divide and contribute to tumorigenesis, although this cycling population was 
unable to reinitiate tumors [101]. These results emphasize that a cycling subset of CSCs 
contribute to tumor progression, although they may be intrinsically sensitive to treatments 
targeting rapidly proliferating cells. Slower-cycling CSCs are important in tumorigenesis 
and in driving recurrence of disease, especially in the context of a post-chemotherapeutic 
setting. 
 
Protein and Biomarker Expression 
While these data suggest that tumor-initiating cells have the capacity for continued 
proliferation and differentiation, the identity of CSCs in many solid tumors remains 
unclear. Solid tumors are a complex amalgamation of normal (endothelial cells, 
fibroblasts, immune cells, etc.) and neoplastic cells whose dynamic interaction may 
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positively [102, 103] or negatively regulate tumor progression [104] and metastasis [105]. 
In the absence of morphologic features to distinguish differentiated cancer cells from stem 
cells, biomarkers of these states are required. Identifying appropriate biomarkers and 
physically separating them from their surrounding microenvironment makes the lineage 
tracing and clonal passaging experiments required for definitive demonstration of CSC 
contributions in solid tumors challenging. It is expected that markers of solid tumor CSCs 
will be unique to their tissue of origin (i.e. markers of breast CSCs will differ from intestinal 
CSCs) just as markers of normal stem cells vary by tissue, there are not yet unified 
markers of solid tumor CSCs within a given tissue, although many candidates have been 
identified. This is illustrated by data from mammary tumors, where a population of cells 
defined by CD44+/CD24-low expression was shown to have an increased capacity for 
tumorigenesis [81]. Other groups have identified CD61/β3 integrin as biologically relevant 
markers used to identify mammary CSCs [106]. Stem cell antigen 1 (Sca1) has also been 
identified as a marker of mammary stem cells, which are also resistant to ionizing 
radiation [83]. This variation in mammary stem cell markers could be a consequence of 
technical variation or differences in the model systems. However, these data might also 
suggest that, in the mammary gland, the CSC phenotype may not be solely dependent 
upon a static, defined set of biomarkers. Instead, the tumorigenic and differentiating 
capacity of CSCs reflects a multitude of intrinsic and environmental factors. In this case, 
the expression of various biomarkers may be an effect and not a cause of more profound 
biological interactions. Indeed, in solid tumors a number of prospective biomarkers have 
been proposed [80, 81, 89, 106-108], but it is unlikely that a uniform set will concisely 
define CSC biology. As compared to carcinomas, tumors of neural crest origin have come 
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from cells whose role in normal physiology involves delaminating from an epithelia 
(epithelial to mesenchymal transition), migrating to a distant anatomical site, and 
colonizing it [109]—features shared with metastatic cells. Similarities between embryonic 
neural crest migration and metastasis of neural crest derived tumors are illustrated by the 
expression of genes such as Slug, which is expressed during both the migration of 
melanocyte precursors from the neural crest and in melanoma during metastasis [110]. 
Mechanisms by which normal stem cells from the neural crest migrate to and colonize 
new tissues may share common biologic means with metastatic cells which are required 
to complete similar tasks to survive and proliferate to colonize new tissues. 
 
Metabolism 
Altered cell metabolism is another shared feature between stem cells, CSCs and 
metastatic cells. The propensity of cancer cells to use primarily aerobic glycolysis as 
opposed to oxidative phosphorylation (OXPHOS) has been known for almost 90 years 
[111] and has been observed in stem cells more recently [112-114]. Ovarian cancer cells 
grown in spheroid culture consumed higher amounts of glucose than their counterparts 
cultured in 2D culture, demonstrated expression of stem-cell related genes and had 
increased tumorigenic capacity [89]. Melanoma cells whose metabolism was comprised 
primarily of aerobic glycolysis readily metastasized, whereas those whose metabolism 
had been shifted toward OXPHOS did not [115]. 
Importantly, while both stem cells and cancer cells have increased glycolytic 
activity as compared to most differentiated and mitotically quiescent cells in the body, 
differences between the two would permit the targeting of cancer cells, while preserving 
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normal stem cell function. An illuminating example can be found in hematopoietic 
malignancies. Hematopoietic stem cells (HSCs), hematopoietic progenitor cells and 
leukemia cells were all found to be sensitive to a reduction in lactate dehydrogenase 
(LDHA). However, the HSCs could tolerate reduced levels of the upstream glycolytic 
enzyme pyruvate kinase (M2 isoform), whereas the hematopoietic progenitor cells and 
leukemia cells could not [116]. The authors propose that this gap between the metabolic 
requirements of HSCs and leukemic cells offers a therapeutically tractable window. 
Together, these results show that normal stem cells, cancer stem cells, and metastatic 
cells all rely heavily upon glycolysis for cell metabolism. The exaggerated sensitivity of 
the cancer cells to changes in cell metabolism opens the possibility of targeting cancer 
cell metabolism to assess and/or treat neoplastic disease. 
 
Metastasis Initiating Cells 
What then are the factors that are required for successful metastatic outgrowth?   
Metastatic lesions are commonly associated with aggressive primary tumors with a high 
mitotic rate, although competition for resources within an actively proliferating tumor 
cannot solely explain the progression of metastatic disease. However, these trends are 
punctuated by numerous exceptions, concluding an imperfect relationship. For example, 
carcinoid tumors readily metastasize despite their generally indolent growth rates [117, 
118]. In the skin, basal cell carcinomas, glioblastoma multiforme [14], and desmoid 
tumors [91] are readily invasive, yet rarely metastatic. Thus, an invasive tumor is not 





During development, cells leave the crest of the neural tube, migrate and become 
incorporated into tissues such as the facial bones, skin and gut. Their delamination from 
the neural tube, migration and accompanying phenotypic changes are known as the 
epithelial-to-mesenchymal transition (EMT). Similar changes are hypothesized to occur 
as epithelial cells from a carcinoma leave the primary tumor and migrate to a potential 
metastatic site. As the epithelial phenotype is also observed in metastatic cells, the 
reverse changes are thought to occur at the metastatic site, a process known as 
mesenchymal to epithelial transition (MET) [87]. Classically, the increased motility of cells 
having undergone EMT is facilitated by decrease in the cell adhesion protein E-cadherin 
and increases in the expression of the intermediate filament protein vimentin and the 
transcription factors Snail, Slug and Twist. Changes in similar gene expression patterns 
have been observed in metastasis [84], however to elicit changes in metastatic efficacy 
the functional consequences of these EMT-like changes must extend beyond facilitating 
cell delamination and migration. 
Expression of the transcription factors Slug and Sox9 have been identified as 
markers of the basal and stem cells in the mammary epithelium [80]. Their expression 
increases the capacity of mammary epithelial cells to form organoids in vitro and 
reconstitute the mammary gland, suggesting that Slug and Sox9 are markers of the stem 
cells in the mammary epithelium. In addition, knockdown of Slug and Sox9 decreased 
formation of macroscopic metastases in an intravenous (IV) experimental metastasis 
model, correlating the stem cell phenotype with efficacy of metastatic colonization at the 
secondary site by disseminated cancer cells. During normal development, Sox9 functions 
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to sustain migrating cells from the neural crest on their journey to the peripheral tissues 
[46]. Although Slug and Sox9 have been detected in human breast cancers, they have 
not been identified as markers in metastatic breast tumors per se [80].  
There exist other normal physiologic processes that mirror activities of metastatic 
tumor cells. Hematopoietic cells and immune cells migrate to a distant site and 
extravasate in response to chemokines. The C-X-C chemokine receptor type 4 (CXCR4) 
and C-X-C motif chemokine 12 (CXCL12 or stromal-derived factor 1/SDF-1) receptor-
ligand relationship functions in normal physiology to attract lymphocytes to sites of 
inflammation [119] or to the bone marrow [120], and is also overexpressed in cancer cells 
that metastasize to the bone [121]. Thus, genes that facilitate metastasis may reflect a 
commandeering of normal developmental and immune programs. Interestingly, 
expression of CXCR4 has been shown to be upregulated by transformation-related 
protein 63 (TP63), conferring increased capacity for colony formation, anchorage-
independent growth and chemotaxis [122]. These results suggest that there is overlap 
between the features of metastatic cancer cells and stem cells, despite the fact that these 
data do not demonstrate direct evidence for increased capacity of CXCR4 expressing 
cells to colonize the secondary site and complete the metastatic cascade. Thus, in many 
cases, metastatic cells are co-opting normal processes and mechanisms to facilitate 
progression of disease. 
 
Mechanisms of Metastasis 
Intriguingly, the induction of EMT results in expression not only of the expected 
mesenchymal proteins, but also of stem cell markers [123]. These mammary cells were 
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also more tumorigenic after having undergone EMT. Expression of Twist was shown to 
be required for metastasis of mammary carcinoma cells [124]. In pancreatic cancer, 
expression of Snail maintained expression of aldehyde dehydrogenase (ALDH), 
considered to be a marker of stem cells [92]. Hypoxia can induce EMT [125] and other 
pro-survival pathways. Subsequent up-regulation of HIF-1α and related target genes is a 
mechanism by which cells increase motility, invasiveness and their capacity to cope with 
increased amounts of unfolded proteins, serving to enhance metastasis [126]. However 
in colon cancer driven by L1, a neural cell adhesion molecule downstream of β-Catenin, 
changes in EMT related genes were not observed in cells overexpressing L1. These cells 
demonstrated increased motility, invasiveness and capacity for metastasis (L1-mediated 
colon cancer cell metastasis does not require changes in EMT and cancer stem cell 
markers). Others would suggest that the changes observed within EMT are within the 
plasticity of epithelial function, and that the changes observed do not necessarily provide 
evidence for differences in cell identity [127]. These results suggest that metastasis and 
the factors facilitating metastatic colonization do not necessarily require EMT, although 
EMT-like changes in gene expression are one means by which to arrive at the same 
biological end. 
Disseminated cancer cells must arrest, survive and proliferate at the secondary 
site to form a metastatic colony. Interestingly, suppression of EMT related genes appear 
to indeed be one component of successful colonization. Loss of the homeobox gene Prrx1 
both abolished the EMT phenotype and was shown to be required for successful 
metastatic colonization [86]. An epigenetic regulator of homeobox genes, Bmi-1, was 
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shown to direct self-renewal in mammary cells [128] and has also been shown to be 
required for tumorigenesis in colon cancer [129]. 
However, overexpression of the homeobox gene Goosecoid was found to increase 
both the motility of breast cancer cells in vitro and the number of metastases in an 
experimental metastasis model [130]. The observation that both overexpression of 
homeobox genes (Goosecoid) and suppression of homeobox genes (Prrx1) result in 
increased metastasis suggest that there remains much to be understood about the 
temporal and spatial regulation of EMT-related genes with respect to their influence on 
metastatic efficacy. Doublecortin-like kinase 1 DCLK1, found in circulating CSCs [85] and 
overexpressed in renal cell carcinoma, was found to regulate EMT in these cells and to 
have a distinct pattern of promoter methylation [131]. These data suggest that epigenetic 
regulation may be a common mechanism regulating the activity of normal stem cells, 
CSCs and metastatic cells that govern cell decisions regarding renewal and 
differentiation. 
 
Contributions of the Niche 
The architecture of the normal stem cell niche is tissue dependent, but in all cases 
it refers to the three-dimensional space surrounding normal stem cells that provides the 
stem cells with physical protection, nutrients and signals that direct stem cell behavior 
[95]. Indeed, one of the functions of the stem cell niche is to regulate the proliferation of 
stem cells to ensure that these cells with such profound proliferative capacity do not divide 
continuously [132]. Thus, the absence of the stem cell niche in vitro to suppress 
unnecessary proliferation also helps to explain the brisk mitotic phenotype observed 
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there, in addition to any added effect the process of conventional cell culture may 
contribute toward selecting for rapidly dividing cells. 
The niche supporting CSCs by definition then differs in this regard [133], as 
proliferating cancer cells have already overridden growth inhibitory signals. Like the niche 
of the normal stem cell, the CSC niche provides the requisite protection and nutrients for 
CSCs [96] and indeed may use the same signaling molecules to influence the mitotic 
activity of CSCs [134]. The importance of maintaining dormancy is also highlighted in the 
context of metastasis. Progression of metastatic disease may occur months to years after 
anticancer therapy, suggesting that disseminated cells existed in a dormant niche or 
state. What are the stimuli that induce this awakening from dormancy and what are the 
signals that would maintain it? Notch signaling was shown to regulate the proliferation 
and capacity for sphere formation of tumor cells in glioblastoma multiforme (GBM) [135]. 
The authors conclude from these data that Notch signaling promotes the CSC phenotype 
in GBM, although an alternative explanation might be that the GBM cells are dependent 
upon the endothelial cells and that the decrease in GBM CSC is an effect of a decrease 
in endothelial cell number. 
By comparison, the metastatic niche refers to the immediate microenvironment 
surrounding disseminated and seeded, potentially metastatic cells and it also helps to 
facilitate cancer cell growth. The secondary site where disseminated cancer cells will 
eventually invade and proliferate as a metastatic colony is termed premetastatic niche 
before the arrival of the tumor cells [136]. Interestingly, the pre-metastatic niche has been 
shown to be “primed” by HSCs from the bone marrow prior to colonization by 
disseminated tumor cells [137]. This action is initiated by factors released from the 
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primary tumor and results in upregulation of fibronectin in the niche fibroblasts and 
increased retention and growth of metastatic cells at the secondary site. Interestingly, the 
features of the normal stem cell niche may also provide necessary interactions to foster 
the growth of metastatic cells to those sites. For example, breast cancer cells metastatic 
to the bone received growth signals initiated by heterotypic cadherin interactions between 
the metastatic cells and the cells forming the osteoblastic and HSC niche [138]. The 
metastatic niche not only supports the growth of metastatic cancer cells, but is also 
dynamically regulated as the cells colonize the secondary site. Exosomes are one means 
by which this remodeling of the metastatic niche is mediated [139]. 
 
Conclusion 
In conclusion, normal stem cells, CSCs and metastatic cells share many features 
including the ability to migrate [88, 110], synergistically interact with the surrounding 
microenvironment or niche for growth signals [102, 132, 137], resist apoptosis [9] and 
recapitulate from clonal origins the heterogeneity observed within the original tumor or 
tissue [74, 80]. The ability to successfully adapt to a changing environment is a necessary 
and shared feature of normal stem cells, CSCs and metastatic cells. Migratory stem cells 
of the neural crest and metastatic cancer cells must adapt to the physical environment at 
new locations while CSCs must adapt to changes in the local environment due to selective 
pressures present within a tumor (e.g. competition for nutrients or oxygen, anti-cancer 
therapy, etc.). One means by which this phenotypic plasticity is accomplished both during 
development and in cancer progression is by epigenetic regulation of gene expression. 
Dysregulation of the epigenome has already become a therapeutic target for cancer [140]. 
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Requirements of a CSC include the ability to self-renew and proliferate indefinitely, 
to differentiate into cancer cells with more limited replicative potential and to be capable 
of reconstituting a tumor upon transfer. In essence, the fulfillment of Koch’s postulates for 
CSCs of each tumor type will definitively establish the identity of the CSCs in various 
tumor types. However, isolation and serial passaging experiments required to definitively 
identify and study ostensible CSCs remain technically challenging, especially in solid 
tumors. For this reason, data that provide evidence for CSC contribution in different 
tumors vary greatly. As the identity of both CSCs and metastatic initiating cells continues 
to be elucidated, future therapeutic interventions must not rely upon a single biomarker 
for targeting and tumor destruction. Rather, a multi-faceted approach utilizing multiple, 
concurrent therapeutic interventions addressing different aspects of CSC biology is likely 
to be required for eradication of tumorigenic cancer cells. The reverse may also be true, 
as discoveries concerning CSCs and metastatic cells may also serve as a model for 
understanding the biology and regulation of normal stem cells, with important human 
applications for regenerative medicine. These considerations highlight significant 
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remaining questions Table 2-2 regarding the in vivo biology of cancer sustaining cells and 
implications for treating patients with cancer.  
As our understanding of the biology and the selective process that produces the 
CSCs and metastatic cells expands, we may begin to therapeutically intercede on multiple 
fronts. What matters most to patients in distinguishing normal stem cells, CSCs and 
metastatic cancer cells is the identification of therapeutically targetable features. 
Ultimately, the relevance of our understanding this biology will be determined by the 
degree to which improved treatments produce better outcomes for patients with recurrent, 
disseminated and metastatic cancer. 
  
 What is the in vivo mitotic rate of cancer stem cells and metastatic cells? 
 What triggers the awakening from dormancy of cancer stem cells that causes recurrence? 
 What makes CSC and metastatic cancer cells genetically unstable? 
 Why is the genetic instability from CSCs and metastatic cancer cells not self-limiting? 
 What therapeutically targetable featuresdistinguish CSCs from normal resident stem cells and 
other cells within the tumor? 
 What traceable biomarkers can be used to detect CSCs? 
 How will knowledge of CSCs direct patient treatment and follow-up? 
Table 2-2: Remaining Unanswered Questions 
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 – Quantitative Image Analysis Reveals Requirements for Metastasis 
Suppression by KISS1 
 
Introductioniv 
Imaging plays a critical role in assessing components of living systems and 
understanding their biology as a whole. Qualitative imaging data are striking and give 
insight into biologic function, but quantitative analysis of imaging data remains 
challenging. Large variations in signal intensity, shape, or distribution can complicate 
objective and quantitative image analysis [142]. Such complex variations are often 
present within living systems and increase with the range of imaging depth [143]. While 
methods such as confocal microscopy allow for the independent imaging of each focal 
plane for subsequent data compilation, data collected using standard epifluorescence 
microscopy, in vivo imaging and time-lapse microscopy often capture images containing 
regions that are both in- and out-of-focus. Thus, out-of-focus objects within an image or 
light scattered as it is transmitted through tissues can skew quantification efforts [144, 
145]. In metastasis research, image data from intact lungs, epifluorescence 
photomicrographs, in vivo luciferase, and Pulmonary Metastasis Assays (PuMA) [146] 
data all present such challenges. In these cases, objectively distinguishing between in-
focus and out-of-focus fluorescent particles within the same image remains challenging.   
PuMA is a powerful tool to study mechanisms of pulmonary metastasis ex vivo 
[147]. However, we found manual quantification of fluorescent image data to be time 
consuming and potentially subjective. In order to overcome these challenges, we 
                                            
iv The following chapter previously appeared in Clinical & Experimental Metastasis, February 
2018, Volume 35, Issue 1-2, p. 77-86. It has been updated here. See References [141]. 
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designed an automated workflow to identify images suitable for automated analysis and 
quantify in-focus regions of interest (ROI) by adapting a method originally developed to 
study sediment deposition [148]. The goal of this workflow is not to replace one method 
of microscopy with another (i.e. confocal with epifluorescence), as we recognize each 
imaging platform has unique strengths and limitations. Instead, we sought to improve the 
objectivity and speed with which complex datasets containing images and features of 
varying quantity and quality can be stratified and analyzed.  
We developed this tool to measure the growth of cancer cells disseminated to the 
lung in order to use the PuMA as a platform to further dissect how the metastasis 
suppressor KISS1 suppresses melanoma lung metastasis [17]. We hypothesized that 
melanoma cells expressing KISS1 would be growth suppressed (i.e., dormant) in the 
PuMA, just as they appear in vivo [149]. Surprisingly, we did not see any difference in the 
rate of growth in the PuMA as measured by area of GFP positive cells in each lung slice. 
Nonetheless, these experiments were useful in developing a tool for automated 
quantification of PuMA and other imaging datasets containing images and data varying 
in quality and intensity.  
 
Methods 
Pulmonary Metastasis Assay 
All animal studies were conducted in accordance with the Guide for the Care and 
Use of Laboratory Animals (National Institutes of Health). Protocol (#2014-2208) was 
approved by University of Kansas Medical Center Institutional Animal Care and Use 
Committee. The PuMA was performed as described [146] with modifications. Female 
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nude mice aged 6-8 weeks were intravenously injected with 50,000 enhanced green 
fluorescent protein- (GFP) expressing C8161.9 cells (human amelanotic melanoma, 
clone 9) [150, 151] suspended in 200 μl of 0-4°C Hanks Buffered Salt Solution (HBSS, 
Life Technologies, #14175-103). Cells circulated for 20 minutes and lodged in lung 
capillaries. Mice were euthanized using CO2 before lungs were insufflated with a 1:1 
mixture of media and agarose using an 18-gauge (GA) needle and 10 ml syringe. After 
tying off the trachea with suture, lungs were extracted and placed in sterile phosphate 
buffered saline (PBS) on ice. Lungs were cut into ~0.5-1 mm sections using sterile forceps 
and microdissection scissors. Sections were placed on media-saturated Gelfoam® 
(Pfizer-Pharmacia & Upjohn Co., #09-0315-08) in a 6-well cell culture plate for incubation 
and imaging. Media was replaced every 2 days. 
 
Experimental Metastasis Assay 
In order to seed the lungs with disseminated melanoma cells, injections were 
performed as previously described [27]. Briefly, 50,000 C8161.9 cells were suspended in 
0-4°C PBS and injected into the tail vein in a volume of 100μl using a 27GA needle and 
1mL syringe. Cells were allowed to grow in vivo for 5 weeks or until the animal was 
moribund. After CO2 induced euthanasia, lungs were imaged grossly using a fluorescent 
dissecting microscope and tumor and lung tissues were collected for analysis. 
Macroscopic metastases were quantified by using the multi-point tool in ImageJ to count 




Cell lines and cell culture 
Human PDAC cell lines (C8161.9) were cultured in DMEM/F12 with 5% fetal 
bovine serum (FBS, Atlanta Biologicals, # S11195), 1% glutamine (Gibco, # 25030-081) 
and 0.25% non-essential amino acids (NEAA, Gibco, #11140-050) in a humidified 
incubator at 37°C. 
 
Immunoblotting 
 Conditioned media was collected from PuMA experiments and spun at 1,000rpm 
to pellet cellular debris. Media was mixed with loading dye and ran on a 10% acrylamide 
gel, transferred to a PVDF membrane and blocked with 5% nonfat milk in Tris buffered 
saline with Tween-20 (TBST). Primary antibody against KISS1 (custom mouse) was 
applied 1:1000 in block and allowed to incubate overnight before applying the anti-mouse 
HRP conjugated secondary (GE #NA931) for 1hr at room temperature.  
 
Image Acquisition 
Lung sections containing disseminated GFP-expressing melanoma cells were 
imaged at days 0, 7, 14 and 21. Each Gelfoam® sponge containing lung sections and 
cancer cells were placed lung side down on a culture dish (MatTek, #P35-G-1.5-20-C) for 
imaging. A Nikon Eclipse TS100 Inverted Microscope, QImaging QIClick monochrome 
CCD camera and Metamorph software were used to take ~30 non-redundant images per 




Figure 3-1: PuMA Image Acquisition and Automated Image Analysis Workflow 
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Figure 3-1 PuMA image acquisition and automated image analysis workflow. (a) Mouse lung sections 
(0.5-1mm thick) containing disseminated GFP-expressing melanoma cells were placed on media-saturated 
gelfoam sponges cultured ex vivo for up to three weeks.  Using an inverted microscope, an average of 30 
non-redundant photomicrographs were recorded per experimental group every seven days. Scale bar for 
cell culture dish is 1 cm. Scale bar for fluorescent image is 50 μm. (b) Cross-section views of lung sections 
containing GFP-expressing melanoma cells within lung section atop Gelfoam® with respect to the focal 
plane of the image. (c) Schematic of the automated workflow used for image analysis. Output from a logistic 
regression model selects analyzable images for subsequent automated analysis. To standardize 
measurement of melanoma growth, only in-focus fluorescent cell clusters/regions of interest (ROI) were 
quantified. In-focus ROI were selected by applying a Gaussian gradient and selecting ROI with a clarity 
value above the in-focus threshold for quantification. Scale bars are 50μm. 
 
GFP-expressing cancer cells were present throughout the lung section. The focal 
plane that optimized the number of in-focus cancer cells was chosen for each image. 
Immunofluorescence (IF) images were collected using a Nikon Eclipse 80i microscope, 
QImaging QIClick 8 bit monochrome camera and an XCite120PC light source. Five 
images per time point were collected and quantified using ImageJ. After imaging, gelfoam 
with lung sections was returned to the 6 well dish and media was replaced. 
 
Image Analysis 
In collecting and analyzing PuMA data, we noted that while some images were 
easily analyzed by automated processing, images with high background skewed analysis 
because the software was not able to recognize all GFP-expressing cells or groups of 
cells. Hereafter, these cell clusters will be referred to as regions of interest (ROI) (Fig. 3-
2a). A step-by-step protocol for the method described (Supplementary 1) and all operating 
scripts required for the protocol are freely available online 
(https://drive.google.com/drive/folders/1zmjp_VW_Pnw7BdyeAut36DS1J6AoJ-
QG?usp=sharing). To develop a training set for machine learning, we used a large set of 
images and manually stratified analyzable images by how accurately the automated 
threshold identified ROI. ImageJ [152] was used for image processing and cell 
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measurements. R was used for statistical analysis, and MATLAB was used to identify out-
of-focus particles. 
To process the images, first the MaxEntropy threshold [153] from ImageJ was 
applied to images from the PuMA. Then, we manually classified images into two groups: 
those that the MaxEntropy threshold accurately identified the fluorescent cells 
(“analyzable”) and those that were not (“unanalyzable”). In both the analyzable and 
unanalyzable image sets, parameters from ImageJ served as explanatory variables 
(numROI, avgArea, avgPerim, avgWidth, avgHeight, avgMajor, avgMinor, avgAngle, 
avgCirc, avgFeret, avgIntDen, avgMinFeret, avgAr, avgRound, avgSolidity). Parameter 
descriptions are provided in Table 3-1 and Supplemental Fig. 3-4a.  
Next, we used these explanatory variables to fit a multivariate logistic regression 
against the outcome variable of whether an image was analyzable or unanalyzable. 
Features which contributed significantly to distinguishing analyzable and unanalyzable 
images were used to stratify future image datasets (Table 3-1). Examples of analyzable 








Figure 3-2 Validation of image analysis measurements and image stratification. (a) Image of 
disseminated GFP-expressing melanoma cells in living lung tissue. Raw image (monochrome), image 
negative, image after thresholding, and cancer cell(s) identified by ImageJ are shown. In-focus cell 
clusters/ROI are retained while out-of-focus particles are excluded. Width of cell cluster measured by 
ImageJ is scaled correctly. Scale bar is 50 μm. (b) Comparison of representative analyzable and 
unanalyzable images stratified by the logistic regression model. Raw images, negatives and ROI identified 
after applying the Gaussian gradient to identify in-focus ROI are shown. Analyzable images show correctly 
identified ROI, while unanalyzable images do not. Scale bars are 50μm. (c) Microscopy images of GFP+ 
control cells on Day 0 and Day 21 as seen by IF (upper panels) staining for GFP or live cell inverted 
epifluorescence microscopy (lower panels). Scale bars are 20μm (IF) and 50μm (image analysis). (d) 
Figure 3-2: Validation of Image Analysis to Measure Tumor Cell Growth 
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Quantification of tumor cell growth in the PuMA at Day 0 and Day 21 as measured by IF (upper graph) and 
image analysis (lower graph). Comparison of image analysis quantification with immunofluorescence (IF) 


















Table 3-1: Logistic Regression Identifies Features Predicting Analyzable Images  
ROI Feature 
(Coefficients) 
Definition Estimate Std. Error z value Pr (>|z|) 
Width 
Longest continuous horizontal 
dimension 
88.840 19.330 4.596 4.300E-06 *** 
Feret’s 
Diameter 
Longest distance between 
any two points 
-94.700 21.980 -4.308 1.650E-05 *** 
Height 
Longest continuous vertical 
dimension 





-15.360 4.462 -3.442 0.001 *** 
Perimeter Length of outside boundary 





3.296 1.397 2.359 0.018 * 
Roundness 4 x 
Area
π x [Major Axis]²
 -3.214 1.421 -2.261 0.024 * 
Circularity 4π x 
Area
 [Perimeter]²
 -3.444 1.920 -1.793 0.073 ^ 
Minimum Feret 
Minimum caliper diameter -30.460 23.140 -1.316 0.188 
Area 
Area of the selection in 
square pixels 
2.454E+09 1.883E+09 1.303 0.193 
Minor Ellipse 
Secondary axis of best fitting 
ellipse 
-19.260 15.580 -1.236 0.216 
Angle 
Angle between primary axis 
and line parallel to the X-axis 
of the image 
0.929 0.935 0.993 0.321 
Major Ellipse 
Primary axis of best fitting 
ellipse 
7.788 16.200 0.481 0.631 
Feret Angle 
The angle (0-180 degrees) of 
the longest distance between 
any two points along the 
selection boundary (Feret’s 
Diameter) 
0.445 1.103 0.403 0.687 
 
Table 3-1 Output of multivariable logistic regression. For each region of interest (ROI) feature assessed, 
the estimate, standard error, z value, probability that a value would be greater than the z value, and 
assigned significance codes are shown. Description of coefficients adapted from ImageJ User Guide 







The outcome of our logistic regression was used to set a threshold for classifying 
which images were analyzable. To determine this threshold and assess prediction 
performance, we conducted a cross-validation using our test dataset by comparing 
original estimates of image analyzability from the multivariate analysis to the cross-
validated model (Supplemental Fig. 3-4b). The probability threshold was set by 
constructing a 2x2 table comparing images determined to be analyzable by manual or 
automated stratification and determining which image probability value (0.57) gave the 
fewest misclassified images. Images with a predicted probability below this threshold 
were excluded from further analysis, while images with a probability above it were 
retained for further analysis. Comparison of automated and manual image stratification is 
summarized in Table 3-2. Overall, automated stratification performed well as a test for 
whether or not an image was analyzable with positive and negative predictive values of 













Table 3-2: Accuracy of Image Classification by Logistic Regression 
 
  
Manual Stratification (Truth) 
 
  




















Total 1742 400 2142 
 
Table 3-2 Comparison of manual and automated image stratification. 
 
Finally, we selected only in-focus ROI for analysis using a method originally 
developed to remove out-of-focus ROI from images in sediment deposition research 
[148]. First, a clarity value is calculated for each ROI by applying a Gaussian gradient 
smoothing function. The threshold for in-focus ROI was determined by comparing a series 
of gradient-produced images with the original image. A clarity value threshold was set 
which distinguished between in-focus and out-of-focus ROI (Fig. 3-1b, 3-1c, 3-2a, 3-2b). 
ROI with a sharper gradient (larger value) than the clarity value were retained and the 
area was quantified, while ROI with a more gradual (smaller) gradient than the clarity 
value were considered out-of-focus and excluded. To verify our image analysis measured 
cell growth accurately, we compared image analysis measurements to direct 
measurements of cell growth using IF of GFP positive cells at Day 0 and 21 (Fig. 3-2c, 3-
2d). We observed similar growth trends using these techniques, validating the 
measurements made by image analysis. Thus, we standardized the ROI which were 
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selected before calculating the surface area of the ROI. Surface area of the in-focus 
fluorescent ROI as compared to the total area imaged was then used as a proxy for cell 




Logistic regression, one-way ANOVA, Student’s t-tests and graphing were performed 
using R (Vienna, Austria) [154] and MATLAB [155]. 
 
Results 
Our goal was to develop an automated workflow whereby epifluorescence images 
could be objectively quantified (Fig. 3-1a). Three tasks had to be automated in order to 
achieve this objective: (1) classification of an image as “analyzable” or “unanalyzable”; 
(2) measurement of ROI/cancer cell features in the image; and, (3) removal of identified 
out-of-focus ROI that might bias the data. 
First, images were classified as “analyzable” or “unanalyzable”. We found that 
some images were amenable to automated cell measurement (task 2) while some were 
not (Fig. 3-1c). All images unable to be measured must be removed from the analysis to 
avoid biased ensemble results (Fig. 3-2b). From our test dataset, we used several 
features measured by ImageJ (Table 3-1, Supplemental Fig. 3-1a) to stratify analyzable 
from unanalyzable images (Fig. 3-2b). Features varied in their ability to identify analyzable 
images and we found that ROI Width, Feret’s Diameter, Height and Aspect Ratio were 
most significant in distinguishing analyzable from unanalyzable images (Pr (>|z|) of 
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4.300E-06, 1.650E-05, 1.760E-04, and 0.001 respectively). Also statistically significant 
were the ROI perimeter, solidity, and roundness (Pr (>|z|) of 0.005, 0.018, and 0.024 
respectively). These features are a result of the statistical model built around our test data 
set and we would expect these features may vary for different data sets.     
     
Table 3-3: Image Selection is Equitable Between Groups and Experimental Day 
Day Group Comparison 
95% Confidence Interval 
(LL, UL) 
P value 
0 B-A -3.189, 1.522 0.637 
0 C-A -2.689, 2.022 0.929 
0 C-B -1.855, 2.855 0.847 
7 B-A -7.080, 10.080 0.893 
7 C-A -10.080, 7.080 0.893 
7 C-B -11.580, 5.580 0.644 
14 B-A -9.010, 8.344 0.995 
14 C-A -8.844, 8.510 0.999 
14 C-B -8.510, 8.844 0.999 
21 B-A -9.562, 6.562 0.880 
21 C-A -5.729, 10.395 0.737 
21 C-B -4.229, 11.895 0.452 
 
Table 3-3 Comparison of number of excluded images between biological groups. No difference was 
identified in the number of images excluded between any groups at any experimental day was identified 
after one-way ANOVA and Tukey’s HSD post-hoc test. 
 
Recognizing that several of the above referenced features may be potentially 
correlated (e.g. perimeter and area), we performed a cross-validation of our test set to 
check for over-fitting of our model and found that our model performed equally well on 
unique subsets of our data (Supplemental Fig. 3-1a). Next, we determined which 
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probability threshold would result in the fewest misclassified images and found this value 
to be 0.57. This threshold was then used to distinguish analyzable and unanalyzable 
images in future experiments. Common causes of unanalyzable images included 
decreased image contrast due to absence of fluorescent cancer cells, pixel oversaturation 
due to robust cancer cell growth, cancer cells outside the focal plane, and increased 
tissue density surrounding bronchioles producing increased background. We also 
compared the automated analysis to manual stratification (Table 2) and found that 
automated stratification was able to identify similar numbers of analyzable images as 
when the same dataset was analyzed manually. 
Next, we wanted to ensure that there was not bias in our model between any of 
the biologically distinct groups analyzed. Over the course of a three-week PuMA 
experiment, lung sections from three biologically distinct lines of GFP-expressing C8161 
melanoma cells were imaged at 0, 7, 14 and 21 days. Approximately 30 images (range, 
14-58) were taken per experimental group at each time with a median and average of 
25.5 and 29.8 images respectively (standard deviation, 10.9). To demonstrate that 
analyzable and unanalyzable images were stratified in an unbiased manner from distinct 
biological groups, we recorded the number of excluded unanalyzable images at each day 
of analysis and compared the means using one-way ANOVA and Tukey’s post hoc test 
(Supplemental Fig. 3-1c). No statically-significant differences were identified between any 
of the groups. These data suggest that the image stratification is functioning equitably 
between biologic groups.  
The second task was the measurement of the ROI features. The key steps 
involved in this process were: (i) removing broad-scale trends in the grayscale color of 
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the image; (ii) creating a binary image of black and white pixels through thresholding; and 
(iii) applying particle measurement routines to obtain quantitative data on the cell 
population (e.g., area, perimeter, long and short axis length and the orientation of long 
axis) for each ROI. Similarity between the ROI observed in the raw image and the ROI 
particles identified by the set thresholds (Fig. 3-2a, 3-2b) suggests that the threshold is 
able to correctly identify ROI of interest.  
The third and final step was to exclude from further analysis any ROI that were 
out-of-focus and might bias the data. In this way, we could objectively select high quality 
images and quantify the area of in-focus ROI to standardize analysis between samples. 
This workflow was developed while we attempted to elucidate the mechanism of 
KISS1 suppression. While the ability of KISS1 to strongly suppress metastasis [17] has 
been demonstrated in multiple tumor types [149] and there have been hints related to 
upstream and downstream regulatory pathways [156], the biochemical underpinnings of 
KISS1 metastasis suppression remain largely unknown. However, previous studies 
showed that KISS1 allows all steps prior to colonization of secondary sites [28]. As a 
result, we sought to use the PuMA as a model for understanding KISS1 mediated 
suppression in the lung so that we could test what regulates KISS1’s metastasis-
suppressing activity.  
To our surprise, there was no statistical difference in the growth of KISS1-
expressing cells compared to controls (Fig. 3-3a). In some cases, growth in lung 
appeared even greater (Fig. 3-3b). Since secretion of KISS1 is required to suppress 
metastasis [28], we confirmed that KISS1 was still secreted in the PuMA at Day 21 by 
immunoblot (Fig. 3-3c). Together, these data show that the outgrowth of KISS1-
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expressing cells is not due to loss of KISS1 expression. In parallel studies using a 
classical in vivo model, the same KISS1-expressing C8161 cells were still robustly 





Figure 3-3: KISS1 Expression Does Not Suppresses Growth in the PuMA, but 
Suppresses Robustly in vivo 
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Figure 3-3 Comparison of KISS1 Growth Suppression in vivo and ex vivo (PuMA). (a) Representative 
images of growth of GFP control (top) or KISS1 expressing (bottom) C8161.9 melanoma cells at days 
0,7,14 and 21 in the PuMA. Scale bar for fluorescent image is 50 μm. (b) Quantification of PuMA 
experiments by image analysis. No significant differences. n = 3 (c) Immunoblot for KISS1 from conditioned 
media from either GFP control or KISS1-expressing melanoma cells grown in the PuMA demonstrates 
KISS1 remains expressed in the PuMA to D21. (d) Representative images of gross lungs containing vector 
control (top) or KISS1 expressing (bottom) C8161.9 melanoma cells five weeks after tail vein injection 




While the PuMA assay did not faithfully replicate what we had observed in vivo for 
KISS1-expressing cells, the data set obtained afforded an opportunity to refine the 
imaging workflow so that future experiments would be more readily analyzed. Objective 
and quantitative analysis of images containing data from a range of focal planes is difficult 
due to variations in signal intensity and distribution. We recognize all microscopy methods 
have unique strengths and limitations [35, 157, 158]. Methods such as confocal 
microscopy may not suffer as much from large variations in signal intensity. Indeed, this 
workflow is not intended to substitute one microscopy for another. Rather, our goal was 
to improve the capacity for epifluorescence microscopy data, nearly ubiquitous in many 
labs, to be more objectively quantified. Automating image selection may also help reduce 
(remove) bias by applying a standardized method to image selection for analysis, rather 
than leaving the decision to a single observer. While we acknowledge that our initial 
stratification was empiric and could be a source of potential bias, we also demonstrate 
that the complex signal differences between analyzable and unanalyzable image 
parameters were quantifiable and could be used to objectively select of images useful for 
automated analysis in future experiments. This platform mirrors other machine learning 
approaches such as non-negative matrix factorization, Random Forest classification, or 
Potts models [159, 160].  
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Using this workflow, we measured growth of disseminated cancer cells as a 
function of in-focus GFP-positive surface area in lung tissue. This method has immediate 
utility in the PuMA, but might also be applied to in vivo data such as the quantification of 
luciferase signal in whole animals with metastases [158]. While our model identified a 
number of features within an image to be significant in stratifying images, the features 
identified for other types of data are likely to vary greatly. This flexibility lends itself to the 
objective analysis of a potentially broad range of biological imaging data. For example, 
comparing relative roundness versus spindle morphologies could assess epithelial-to-
mesenchymal transition, which contributes to some cells’ metastatic or invasive potential 
[161, 162]. Additionally, using multiple features of the ROI creates a stronger tool for 
distinguishing in-focus from out-of-focus ROI than would a single modality, such as a 
gradient based on pixel saturation alone [163].  
Despite the disappointment that PuMA did not mimic in vivo results in the C8161 
KISS1 melanoma model, the results may still have provided clues regarding mechanism 
of action. KISS1-expressing cells still proliferated. Since we previously showed that 
C8161 cells do not express the KISS1 receptor GPR54 [28], eliminating autocrine 
feedback of KISS1 on this receptor as a potential mechanism, the hypotheses related to 
paracrine mechanisms or alternative feedback [164] are supported. Three possibilities 
exist for the lack of consistency between the in vitro and in vivo data: (1) a factor required 
to suppress growth of KISS1-expressing cells is missing in PuMA; (2) a molecule that 
promotes growth of KISS1-expressing cells is ‘uncovered’ in PuMA; or, (3) KISS1 
suppresses at a step other than proliferation at the secondary site and that step is not 
measured by PuMA. Perhaps the secretion of KISS1 alters the microenvironment in vivo 
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such that dormancy is induced in disseminated melanoma cells? While effects on 
lymphoid derived immune cells are unlikely due to the fact that suppression is observed 
in nude mice lacking fully developed T cells, potential suppressive effects from KISS1 on 
myeloid derived immune cells, such as macrophages, have not been ruled out. Such a 
result might also explain the absence of suppression in ex vivo models if such suppressive 
immune cells are not recruited in the short time disseminated cancer cells circulate before 
collection of the lungs for PuMA culture ex vivo. These data, taken together with results 
from all of the other assays measuring steps of metastasis in vitro, emphasize that the 
whole is indeed more than the sum of its parts; measuring steps of the metastatic cascade 
independent of their context in vivo provides observations which may not necessarily be 
representative of the entire process of metastasis. The ability of this system to engage 




Supplemental 1 is a comprehensive step-by-step protocol for the use of the workflow 
and the scripts which are freely available: 
https://drive.google.com/drive/folders/1zmjp_VW_Pnw7BdyeAut36DS1J6AoJ-
QG?usp=sharing   








Figure 3-4 Region of interest (ROI) features and statistical validation of image stratification mode. (a) 
Illustration of measurable and statistically significant (red) or not (black) features of ROIs between 
analyzable and unanalyzable images. These features were used to stratify analyzable images used for 
further analysis from unanalyzable images (excluded). Scale bar is 50 μm. (b) Cross-validation results 
from logistic regression comparing test set and new sample sets. (c) Comparison of mean number of 
excluded images from three biologically distinct groups for each time point. One-way ANOVA followed by 
Tukey’s post hoc test found no significant differences were found between groups suggests all groups 
were excluded equally. For each group, degrees of freedom = 2 and residuals = 15.  
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 – ITIH5 as an Inhibitor of Pancreatic Cancer Metastasis 
Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer; liver metastasis is 
common and on average only two percent of patients diagnosed with metastatic disease 
survive five years or more. In order to identify genes contributing to metastasis of PDAC 
to the liver, we performed a genome-wide screen in a non-metastatic human PDAC cell 
line, S2-028 [29]. This screen identified two suppressors of pancreatic cancer metastasis, 
one of which was Inter-Alpha-Inhibitor-Heavy-Chain 5 (ITIH5). We used shRNA 
knockdown and overexpression experiments were performed in human PDAC cell lines 
(MIAPaCa-2, BxPC-3, Panc-1 and SUIT2 derivatives S2-028 and S2-007). These data 
revealed that expression of ITIH5 correlated with decreased cell migration, invasion and 
liver metastasis, but had only a marginal effect on growth of the primary tumor in vivo. 
Knockdown of ITIH5 in S2-028 cells increased migration, invasion, mesenchymal shape 
and liver metastasis. Conversely, in the highly metastatic human PDAC cell line S2-007, 
which has low endogenous expression of ITIH5, re-expression of ITIH5 reduced cell 
motility, invasion, and liver metastasis and was correlated with a change to an epithelial 
morphology.  Interestingly, observations from normal physiology show similar correlations 
between reductions in cell motility/invasion and expression of ITIH5. For example, ITIH5 
expression increases in the murine placenta during gestation [165], and in humans ITIH5 
is expressed in what appears to be the syncytiotrophoblast of term placenta after 
endometrial invasion has ceased [29].  
Decreased expression of ITIH5 has been reported in  a number of other human 
cancers, including breast [54], lung [62], bladder [61], stomach [66], colon [166], acute 
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myeloid leukemia [65] and ependymoma [64]. In breast cancer, expression of ITIH5 has 
been correlated with changes in expression of integrins, other tumor suppressors and 
changes in the activation of small GTPases [68]. Such changes in the activation of 
GTPases may help explain the observed changes in morphology upon ITIH5 expression 
but a definitive mechanism of metastasis suppression remains to be elucidated.  
ITIH5 is a secreted protein and is thought to play a role in stabilization of the 
extracellular matrix like other members of the Inter-alpha-trypsin inhibitor family [56], but 
relatively little is known about the localization of ITIH5. To our knowledge, there have 
been no reports describing the subcellular localization of ITIH5 in PDAC. Furthermore it 
is known that the Inter-alpha-trypsin family of proteins undergo extensive post-
translational processing [167], but it was not known if ITIH5 undergoes similar processing 
or if such cleavage and crosslinking events have any significance with respect to ITIH5’s 
function as a metastasis suppressor. Thus, we began by identifying where ITIH5 is 
expressed in human PDAC and observed how ITIH5 is processed to understand whether 
localization or processing have any functional significance in the mechanism of 
suppressing liver metastasis. Finally, since ITIH5 is a secreted extracellular matrix 
protein, we tested whether secretion of ITIH5 was required to suppress metastasis by 
deleting the N-terminal secretion sequence, creating a non-secreted ITIH5 expression 
construct (ITIH5Δs). Determining the mechanism by which ITIH5 suppresses PDAC liver 
metastasis may help establish future therapeutic targets related to ITIH5 and ultimately, 






Cell lines and cell culture 
Human PDAC cell lines (SUIT2 derivative S2-007 and MiaPaCa-2) were cultured 
in DMEM/F12 (Gibco Cat #11330-032) with 5% fetal bovine serum (FBS) (Cat #S11195, 
Atlanta Biologicals, Atlanta, GA), 1% glutamine (Gibco, #25030-081) 0.25% non-essential 
amino acids (Gibco, #11140-050) and 1.5 and 1.0μg/mL Puromycin respectively (Gibco, 
#A11138-03) in a humidified incubator at 37°C. 
 
Cell Migration (Scratch) Assays 
PDAC cell lines were cultured using the conditions described above. Cells were 
plated in 6 well plates (Corning, Cat #07-200-83) and grown to near confluency after 48 
hours of growth in a humidified incubator at 37°C (1 or 2 million cells). Plates were 
scratched using a 200μl filtered tip (Avant, Cat#ARS-200) with the plate lid as a guide. 
Two vertical and equally spaced scratches were made in each well. Plates were then 
rinsed twice with Phosphate Buffered Saline (PBS) and culture media was replaced 
before phase contrast imaging using a Nikon Eclipse TS100 Inverted Microscope, 
QImaging QIClick monochrome CCD camera and Metamorph software. Surface area of 
the open space between cells was measured using ImageJ software [152] and the Wound 
Healing Tool macro [168]. For each time point, three images per scratch and two 
scratches per experimental group were recorded for each experiment. All experiments 





Cell fractionation experiments 
Cytoplasmic-Nuclear fractions were separated according to the manufacturer’s 
instructions using the NE-PER™ Nuclear and Cytoplasmic Extraction kit (ThermoFisher, 
#78835). Membrane-Cytoplasmic fractions were separated according to the 
manufacturer’s instructions using the Mem-PER™ Plus Membrane Protein Extraction kit 
(ThermoFisher, #89842).  
 
Immunoblotting 
Cells cultured in vitro were lysed using 1X RIPA buffer (Millipore, #20-188) with 
1% protease-phosphatase inhibitor (Thermo, #78411) on ice for 15 minutes before 
centrifuging (13,000 RPM) for 15 minutes. Protein concentration was determined using a 
BCA assay (Thermo, #23227). Whole cell lysates were denatured using NuPAGE LDS 
Sample Buffer (Invitrogen, #NP0007) with 10% BME (Sigma, #60-24-2) at 95°C for at 
least five minutes before separation using either a 4-20% gradient SDS-PAGE gel (Bio-
Rad, #567-1039) or a 10% gel (Bio-Rad Acrylamide, #161-0158) and proteins were 
transferred to PVDF membranes (Bio-Rad, #170-4156), and blocked for at least one hour 
using 5% milk in Tris Buffered Saline with Tween-20 (TBST). Antibodies were diluted 
1:1000 in blocking solution and membranes were allowed to incubate overnight at 4°C 
(ITIH5: ThermoFisher #PA5-24445, CD44: R&D Systems #BBA10) or for one hour at 
room temperature (GAPDH, Cell Signaling, #2118). Anti-FLAG M2 HRP conjugated 
mouse monoclonal antibody (ThermoFisher, #A8592) were used to detect FLAG. 
Secondary antibodies (Anti-Rabbit: GE #NA934V, Anti-Mouse: GE #NA931V) were 
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diluted 1:5000 in block and were allowed to incubate for one hour at room temperature in 
protein block.  
 
Immunoprecipitation from Conditioned Media 
Cells cultured in vitro were allowed to grow to near confluency for 48 hours. Cells 
were washed twice with PBS, and media was replaced with fresh media. Cells were 
allowed to grow for 24-48 hours and conditioned media was collected. Conditioned 
media was centrifuged at 12,000rpm for 3 minutes at 4°C to remove debris. 
Supernatant was transferred to clean, pre-chilled microcentrifuge tubes (~1ml/sample). 
Samples were pre-cleared from nonspecific interactions to agarose beads by adding 10-
20ul agarose beads and allowed to incubate with rotation for 1hr at 4°C. Samples were 
then centrifuged at 12,000rpm for 3 minutes at 4°C and supernatant was transferred to 
new pre-chilled microcentrifuge tubes. ITIH5 (ITIH5, ThermoFisher, #PA5-24445), Anti-
FLAG (ThermoFisher, #F1804-200G), or control antibodies (Cell Signaling, Mouse IgG 
#5415, Rabbit IgG #2729) were added and allowed to incubate at 4°C with inversion 
overnight. The next day, 20µl A/G beads per 1 ml were added and allowed to incubate 
overnight at 4°C as described above. The next day, samples were centrifuged at 
12,000rpm for 10 minutes at 4°C to precipitate beads. Supernatant was aspirated and 
beads were washed with 250µl ice cold PBS and centrifuged at ~3,000rpm at 4°C for 
five minutes (x3). 20ul loading dye with mercaptoethanol was added to resuspend each 
bead pellet and samples were boiled for 5 minutes at 95°C. Samples were loaded on 




RhoA Activation Assays 
Activated RhoA was detected using an immunoprecipitation based assay (Active 
Rho Detection Kit, Cell Signaling #8820). Cells were grown in culture, lysed and protein 
quantified using a BCA assay. 500µg of protein were collected, mixed with GST-Rhotekin-
RBD beads and GTP bound proteins were eluted. Positive controls were treated with 
GTPγS before elution, while negative controls were treated with GTPγS but no GST-
Rhotekin-RBD beads were used to bind GTP substrates before eluting. Eluate was ran 
on a gel and blotted for Rho proteins (#8789), RhoA (#2117) or RhoC (#3430) using 
immunoblotting described above.  
 
Extracellular Vesicle (EV) Isolation 
Exosome purification was performed as previously described [169] with minor 
modifications. Briefly, cells were grown to 70% confluence at 48hr after plating in 10 cm 
dishes and washed twice with 1X PBS. Cells were incubated in 7 ml/dish of EV-free 
medium for 36-48 hours before harvesting media. Cells were centrifuged in conical tubes 
in table top centrifuge with swing bucket rotor at 300 g for 10 min at 4°C and then 
transferred to fresh tubes on ice. Supernatant was centrifuged at 2,000 g for 10 minutes 
at 4°C. Supernatant was transferred to autoclaved 500 ml Nalgene bottles and 
centrifuged at 16,500 g for 30 min at 4°C in a floor model centrifuge with a fixed-angel 
rotor. Supernatant was transferred to thin polymer open top tubes (Fisher, #03-126)  and 
centrifuged at 110,000 g (24,300 rpm) in an ultracentrifuge using a swing bucket 
(SureSpin630 6X16) rotor for 1.5 hours at 4°C. Supernatant was removed and pellets 
were resuspended in 1 ml ice cold PBS before centrifuging at 110,000 g (24,300 rpm) in 
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a floor model ultracentrifuge using a swing bucket (SureSpin630 6X16) rotor for 1.5 hours 
at 4°C. Supernatant was removed and pellet was resuspended in 20-40μl PBS before 
lysis, protein quantification and western blotting.  
 
Trypan blue cell proliferation assays 
To measure cell proliferation in vitro, 1.0 x 104 human PDAC cells were plated in a 
6-well cell culture dish (Corning, Cat #07-200-83) using culture conditions described 
above. At days 1, 3, 7, 10 and 14 cells were washed with 1X PBS (Gibco #10010-023) 
and detached using trypsin-EDTA (Gibco #25200-056) until cells were free-floating. An 
equal volume of media with fetal bovine serum (FBS, Atlanta Biologicals, #S11195) was 
used to create a single-cell suspension. The concentration of cells was determined using 
a hemocytometer (Reichert, Cat #Z359629). Both live and dead cells were counted and 
distinguished by exclusion or passive uptake of trypan blue solution (Sigma, Cat #T8154). 
Experiments were conducted in triplicate and standard errors were calculated.  
 
Plasmids and viral transduction 
The secretion sequence of ITIH5 was removed to create the deleted secretion 
ITIH5 (dsITIH5) mutant. Deletions and restriction sites were inserted using directional 
cloning techniques and verified by restriction digest and sequencing. Lentiviral 
transduction was used to introduce the construct into PDAC cells. DNA was amplified 
using Gold competent cells. Plasmids were transfected into packaging cells according to 
Polyplus transfection recommendations using jetPRIME Transfection reagent (Polyplus, 
#114-15) and Polyplus Buffer (Polyplus, #712-60). This was added to packaging cell 
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media and transduction was allowed to occur overnight. More media was added at 24 
hours and 48 hours after transfection, viral supernatant was collected, precleared using 
centrifugation and filtered through 0.45 low protein-binding filters (GVS, #09-977-751) and 
applied to cells. Transductions occurred for 3 days and then cells were allowed to rest in 
culture media before undergoing puromycin selection for 4 days. 
 
Experimental metastasis assay—intrasplenic injections 
In order to measure growth of disseminated pancreatic cancer in the liver, PDAC 
cells were injected intrasplenically into 6-8 week old athymic Nude-Foxn1nu mice 
(Envigo/Harlan) and were allowed to circulate and seed the liver via the portal circulation 
for two minutes. A splenectomy was subsequently performed to remove intrasplenic 
tumor burden and allow for outgrowth of liver metastases. These procedures were 
performed as previously described [24, 29]. For S2-007, 5 x 105 were injected in 100µl 
Hanks Balanced Salt Solution (HBSS, Gibco, #14175-103) and allowed to grow for 4 
weeks, or until the mouse was moribund and required euthanasia.  
 
Quantification of Metastases 
Quantification of gross liver metastases was accomplished with the assistance of 
a Nikon SMZ1500 Stereomicroscope and 1-10mm reticle. Length and width of each 
metastasis was measured. All lobes of the liver were counted and both superior and 
inferior surfaces of the liver were assessed for metastases. Metastases visible from both 
sides of the liver were only counted once. Histologic metastases were measured from 
hematoxylin and eosin (H&E) stained paraffin sections. Livers were fixed in formalin 
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(Fisher, # SF-98-4) for at least 24 hours before dehydrating and paraffin embedding. 
Sections were cut on a microtome to 7 µm and H&E stained using standard methods. 
Five H&E images were taken at 4x magnification from each liver and three mice per group 
were assessed. Area of metastases and liver visible were recorded using the multi-point 
tool in ImageJ. Percentage of liver area occupied by metastases was recorded and 
compared between experimental groups.  
 
Statistical Analysis 
All statistical analysis was carried out using R software [154]. For comparisons between 
groups, one-way ANOVA was used followed by Tukey’s post hoc test. 
 
Results 
Expression, localization and peptide processing of ITIH5 in human PDAC 
In breast cancer, ITIH5 is a secreted extracellular matrix protein with distinct 
functional domains [54, 170]. The Inter-α-Inhibitor Heavy Chain Family (IαI) members are 
typically cleaved and covalently linked by chondroitin sulfate [167]. Consistent with this 
pattern, ITIH5 contains a cleavage site at D681-V686 [54], dividing the ~105kDa protein 
into ~75kDa and ~29kDa fragments. The ITIH5 antibody used binds an epitope on the N 
terminus of the cleavage site and the FLAG epitope is present at the C terminus of the 
protein (Fig. 4-1a), so if ITIH5 were cleaved, we would expect to see bands detecting 
ITIH5 with this antibody at ~75 (cleaved N fragment), ~105 (full length ITIH5) or ~150kDa 
(covalently linked 75kDa fragments). Similarly, we would expect to see fragments at ~105 
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Figure 4-1: ITIH5 is secreted and cleaved extracellularly in PDAC cells. 
 
Figure 4-1 Expression and localization of ITIH5 and non-secreted ITIH5Δs. A) Organization of ITIH5 
domain structure labeled by amino acid number for full length ITIH5 (ITI) and secretion-deficient (Δs) 
expression constructs, domain map adapted from Himmelfarb et al, 2004. Grey bars: secretion signal 
peptide (SP), vault protein inter-alpha-trypsin domain (VIT), von Willebrand type A domain (vWA), cleavage 
site (CS), multicopper oxidase domain (MCOD). Black bar: FLAG tag (FLAG). B) Immunoprecipitation of 
extracellular ITIH5 from conditioned media using ITIH5 antibody (binds on N terminal side of cleavage site 
at AA578-606) and FLAG antibody (binds on C terminal side of cleavage site after end of ITIH5 open 
reading frame). C) Western blotting of exosome preparations (SIZE RANGE) for ITIH5. D) Western blotting 
of ITIH5 in cellular fractions enriched for either cytoplasm/nucleus or membrane/cytoplasm. Abbreviations: 




We hypothesized that the secretion of ITIH5 would be required for the suppression 
of pancreatic cancer metastasis and first sought to characterize the localization of ITIH5 
in PDAC. We expressed both secreted (ITIH5) secretion-deficient ITIH5 (ITIH5Δs) 
constructs in the highly metastatic and low endogenous ITIH5-expressing human PDAC 
cell lines S2-007, and MiaPaCa-2. Levels of expression were similar to endogenous 
levels of ITIH5 observed in cultured pancreatic epithelial cells [29]. In the secretion mutant 
ITIH5Δs, secretion into conditioned media was inhibited (Fig. 4-1b). Interestingly, ITIH5 
appears cleaved extracellularly as indicated by the absence of the 105kDa fragment and 
predominance of the 75 and 29kDa fragments in conditioned media of the ITIH5-
expressing cells. The consensus cleavage sequence (DPHFVV) is predicted to be 
cleaved by chymotrypsin [167] (DPHF│VV), but may also be cleaved by a number of 
putative serine proteases at varying amino acid positions. In this case, the small C 
terminal (29kDa) fragment appears to run at a higher molecular weight due to the 17aa 
added after the ORF (9aa plus 8aa FLAG tag) before the STOP codon in the expression 
construct. Seeing that ITIH5 is secreted extracellularly in PDAC, we looked to see if ITIH5 
was secreted into extracellular vesicles. However, ITIH5 does not appear to be secreted 
into extracellular vesicles (mean particle size of 155nm, Fig. 4-1c), but may be secreted 
directly from Golgi vesicles.  
Next, we performed cellular fractionation experiments to understand the 
intracellular localization of ITIH5. Reagents which separated the cytoplasmic fraction from 
the nuclear fraction, or which separated the cytoplasmic fraction from the membrane 
fraction (or potentially membrane-bound fraction) were used to assess the cellular 
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compartments for ITIH5 expression. Furthermore, the molecular weight of the ITIH5 
expressed was detected with both the anti-ITIH5 and anti-FLAG antibodies, allowing us 
to detect potential protein processing events such as peptide cleavage or dimerization. 
 Interestingly, the ~75kDa and ~29kDa fragments did not appear intracellularly. 
Instead, ITIH5 appeared at its full-length molecular weight of ~105kDa using both the 
ITIH5 and FLAG antibodies (Fig. 4-1d). ITIH5Δs runs at a slightly lower molecular weight 
due to deletion of the 18aa secretion sequence. Crosslinking of the two ~75kDa Inter-
alpha-trypsin N terminal fragments into a ~150kDa dimer does occur and should be 
detectable using the anti-ITIH5 antibody. Indeed, a ~150kDa band is visible in the 
cytoplasmic fraction when separated from the membrane fraction. This suggests that 
ITIH5 may also be cleaved intracellularly, and that the ~75kDa fragment is likely cross-
linked to short chains of chondroitin sulfate or hyaluronic acid to create the ~150kDa dimer 
in an organelle such as the Golgi. We were not able to detect ~29kDa fragment 
intracellularly, perhaps due to degradation during processing. ITIH5 is also visible in the 
nuclear fraction at the ~105kDa molecular weight. Because of the large size of ITIH5, 
transport into the nucleus is anticipated and ITIH5 indeed contains at least three predicted 
nuclear localization sequences (aa500-526, aa732-741, and aa890-919), although it is 
not currently known which potential nuclear localization sequence is required for nuclear 
localization.  
 
Expression of ITIH5 Affects Cell Morphology and Motility  
 Expression of ITIH5 has been shown to alter cell morphology in vitro [68]. We 
expressed ITIH5 in highly metastatic human PDAC cells and observed effects similar to 
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those described (Fig. 4-2a). The effects were most dramatic in the S2-007 cells. 
Interestingly, expression of ITIH5Δs showed an indistinguishable phenotype (Fig. 4-2a), 
despite the fact that this molecule is not secreted (Fig 4-1b). These data imply that an 
intracellular effect could contribute to the metastasis-suppressive effects of ITIH5.  
The pancreatic cancer cell lines in these experiments share activating mutations 
in KRAS, inactivating mutations in p53 and inactivating mutations in p16 (CDKN2A) [171]. 
In order to understand the mechanism of metastasis suppression by ITIH5, we first looked 
to see whether ITIH5 expression affects cell proliferation in vitro. We found that 
expression of either ITIH5 or ITIH5Δs did not significantly affect rates of cell proliferation 
or cell death at steady state (Fig. 4-2b). We have previously reported that expression of 
ITIH5 was correlated with decreased cell motility [29]. We tested the effect of expressing 
ITIH5Δs and found that intracellular ITIH5 also reduced cell motility as measured using 
the wound healing assay (Fig. 4-2c, 4-2d). Together, these results suggest that the 
mechanisms by which ITIH5 induces a rounded cell morphology and slows cell motility 
does not require secretion, but appears to be due to an intracellular role of ITIH5. 





Figure 4-2: Expression of ITIH5 changes cell morphology and migratory capacity. 
 
Figure 4-2 Assessment of secreted (ITIH5) and non-secreted (ITIH5Δs) expression on PDAC cell 
morphology, proliferation, and migration. A) Expression of extracellular and intracellular full length ITIH5 
and intracellular only secretion-deficient ITIH5Δs in metastatic and low-ITIH5 expressing human PDAC cell 
lines S2-007, and MiaPaCa-2 is correlated with rounded cell morphology and tight epithelial-like clustering. 
B) Expression of intracellular and extracellular ITIH5 or intracellular only ITIH5Δs cause no changes in cell 
proliferation or cell death in vitro. C) Expression of both ITIH5 and ITIH5Δs reduced cell motility in an in 
vitro wound healing/scratch assay. D) Quantification of results from wound healing assay, measurement of 




Effects of Intracellular ITIH5 in vitro and in vivo 
Next, we tested whether secretion of ITIH5 was necessary for suppression of liver 
metastasis. We injected human PDAC cells expressing ITIH5 or ITIH5Δs into 6-8 week 
old athymic nude mice intrasplenically and cells were allowed to circulate and seed the 
liver via the portal vein. Strikingly, we saw that non-secreted ITIH5Δs also suppressed 
liver metastasis, indicating an intracellular role for ITIH5 in metastasis suppression (Fig. 
4-3a, b). Animals bearing disseminated tumors expressing ITIH5 or ITIH5Δs showed 
reduced number of macroscopic metastases (median, Control = 13, ITIH5 = 5.5 and 
ITIH5Δs = 3), although only comparison between Control and ITIH5Δs groups reached 
statistical significance (P = 0.029). This could be due to a single large potential outlier in 
the ITIH5 group (28 metastases). Size of macroscopic metastases were also reduced by 
expression of either ITIH5 or ITIH5Δs as measured by the sum of the longest dimension 
of each metastasis (median, Control = 21.5, ITIH5 = 7, ITIH5Δs = 4). Expression of either 
ITIH5 or ITIH5Δs also reduced the number (average, Control = 3.3, ITIH5 = 1.7, ITIH5Δs 
= 1.3) and area occupied (average percent liver occupied by metastases, Control = 0.19, 
ITIH5 = 0.06, ITIH5Δs = 0.07) by histologic metastases (Fig. 4-3c, d). As lung metastases 
are possible in this assay from PDAC cells passing through the liver and lodging in lung 
capillaries, we also assessed the lungs for metastases. No gross metastases were visible 
on the surface of the lung, but in the vector control and ITIH5Δs groups, metastases were 
present in the lung histologically. There was no statistically significant difference between 
the number of lung metastases in these two groups (Fig. 4-3e, f). These results could 
indicate some tissue specificity in growth suppression by ITIH5. For example, it is known 
that lung is a more hospitable microenvironment for PDAC metastases as compared to 
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the liver [172], which might render the metastasis suppressive effects of ITIH5 less 
apparent. Further sampling is underway to determine whether this difference was due to 





Figure 4-3: Intracellular ITIH5 (ITIH5Δs) suppresses liver metastasis. 
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Effects of ITIH5 expression on Rho GTPase Signaling 
We observed that expression of both ITIH5 and ITIH5Δs in human PDAC cells 
induced a rounded, epithelial-like cell morphology. Activation of the small GTPases of the 
Rho family are responsible for mediating changes in cell morphology and migration [173], 
phenotypes both affected by expression of ITIH5 (Fig. 4-2a, c). Previous work has shown 
that expression of ITH5 increases activation through the small GTPase RhoA [68]. RhoA 
is thought to have a tumor-suppressive role in cancer [174], although data also exist 
supporting a potentially oncogenic role [175]. We hypothesized that expression of ITIH5 
might be altering activation through RhoA, and thereby altering both cell morphology and 
metastatic efficacy. 
Furthermore, ITIH5 is predicted to bind hyaluronic acid (HA), which can also signal 
through Rho GTPases [176]. CD44 is a receptor for HA [177] and also a potential marker 
of cancer stem cells (CSCs) and prognosis in PDAC [178]. Given that binding of CD44 to 
HA can activate Rho GTPases downstream [179], we first asked whether ITIH5 might 
affect expression of CD44 upstream of RhoA to modulate activation of RhoA (Fig. 4-4a). 
However, it does not appear that either secreted ITIH5 or non-secreted ITIH5Δs alter the 
expression of CD44in MiaPaCa-2 cells. Next, we tested whether expression of ITIH5 
might alter the activation of Rho GTPases using a Rhotekin-RBD bead-mediated 
pulldown assay for activated Rho. First, we validated the assay using a pan-Rho antibody 
Figure 4-3 Assessment of secreted (ITIH5) and non-secreted (ITIH5Δs) expression on metastatic 
efficacy of highly metastatic S2-007 cells. A) Images of livers in situ and ex vivo from intrasplenic 
experimental metastasis assay. Human PDAC cells (S2-007) were transduced with control vector, ITIH5 or 
ITIH5Δs. B) Quantification of median number and median size of gross liver metastases. C) Low and high 
magnification of histologic sections of liver containing metastases. D) Quantification of area containing liver 
metastases. E) Low and high magnification images of lung sections from experimental metastasis assay. 
F) Quantification of lung metastases from intrasplenic injection. 
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and demonstrated that no signal was detected when the samples were activated with 
GTPγS and the Rhotekin-RBD beads were omitted (negative control), that GTPγS-
activated samples could be detected when pulled down with Rhotekin-RBD beads 
(positive control), and that therefore GTP-bound Rho was detectable (Fig. 4-4b). We 
hypothesized that expression of ITIH5 might increase activation of RhoA and thereby 
mediate changes in cell morphology and metastatic efficacy. However, when we 
assessed levels of active (GTP-bound) RhoA in S2-007 and MiaPaCa-2 cells, we did not 
see significant increases in activated RhoA in the metastasis-suppressed ITIH5 and 
ITIH5Δs groups (Fig. 4-4c). We also observed no significant change in GTP-bound 
(active) RhoC that might correlate with observed metastatic efficacy (Fig. 4-4d). As a 
negative result, this RhoC experiment was not repeated and so interpretation may be 
limited. In summary, we found no consistent difference in activation of RhoA or RhoC 
between control cells and ITIH5 or ITIH5Δs-expressing cells. Together, these data 
suggest that despite the activation of RhoA observed after expression of ITIH5 in breast 
cancer [68], neither HA/CD44 signaling nor direct activation of RhoA are likely responsible 





Figure 4-4: Intracellular ITIH5 Expression Does Not Affect RhoA/CD44 Signaling 
 
   
  
Figure 4-4 Comparison of CD44 expression and activation of Rho GTPases with expression of ITIH5 
and non-secreted ITIH5Δs in human PDAC. A) Western blot for CD44 and GAPDH in PDAC. B) Validation 
of GTP pulldown assay showing Rhotekin-RBD bead mediated pulldown of GTP bound (active) Rho (pan 
Rho antibody), samples activated with GTPγS but omitting bead pulldown (negative control), and samples 
activated with GTPγS pulled down with Rhotekin-RBD beads (positive control). C) Assessment of RhoA 
activation (GTP-bound RhoA) in human PDAC cells (S2-007 and MiaPaCa-2) transfected with control 





Expression of ITIH5Δs in S2-007 cells slowed cell migration, reduced liver 
metastasis following intrasplenic injection into athymic mice, and was associated with an 
epithelial morphology. Effects of expressing ITIH5Δs mirrored those of expressing full-
length, secreted ITIH5. Together, these data suggest that ITIH5 attenuates PDAC 
metastasis via an as-yet unidentified intracellular mechanism.  
We have shown that secretion of ITIH5 is not necessary to suppress liver 
metastasis in PDAC, suggesting that there may be an intracellular role for ITIH5 in 
suppressing metastasis. This result was unexpected, as most of what is known about the 
biology of the inter alpha trypsins (IαI) has focused on their extracellular role, due to their 
binding of hyaluronic acid (HA) [180], the fact that they are secreted and their structural 
similarity to serine protease inhibitors. However, this binding to HA may be to short HA 
polymers which are present intracellularly [167] and not only the multi-kilodalton HA 
polymers that add structure and hydrophilicity to the extracellular matrix (ECM). 
Furthermore, we provide what we believe to be the first evidence that ITIH5 is cleaved 
extracellularly, processed into fragments of differing molecular weights and is localized in 
both the cytoplasm and nucleus in human PDAC. These observations regarding the 
subcellular localization of ITIH5 are novel and further work will be required to understand 
the functional significance of this localization and processing with respect to metastasis 
suppression. At present, both cytoplasmic and nuclear localization of ITIH5 were 
observed in both metastasis-suppressed groups (ITIH5 and ITIH5Δs), so it is unknown 
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whether cytoplasmic, nuclear, or both localizations are required for suppression of 
metastasis.   
Although this result was somewhat surprising, intracellular roles of ECM proteins 
are not entirely unknown in cancer. For example, MUC1 is a component of the ECM and 
also acts intracellularly to affect cell signaling and gene transcription [181]. Indeed, 
intracellular ITIH5 caused similar changes in cell morphology, migration and suppression 
of PDAC metastasis as secreted ITIH5, strongly suggesting an intracellular mechanism 
of metastasis suppression.  While we did observe changes toward a rounded, epithelial-
like phenotype in PDAC just as was observed in breast cancer [68], but we did not 
observe similar activation of the tumor suppressor RhoA. These differences may be due 
to tissue-specific effects of ITIH5, or perhaps the changes in morphology are due to 
changes in expression of other regulators of cell morphology, such as integrins. In breast 
cancer, ITIH5 was shown to alter expression of integrins, presenting another potential but 
unassessed candidate to explain the observed changes in PDAC morphology. 
Furthermore, we did not observe changes in expression of CD44, which also binds HA to 
activate RhoA signaling and may serve as a cancer stem cell marker in PDAC [182]. In 
any case, these data suggest that in PDAC, neither activation of RhoA nor modulation of 
CD44 expression is required for suppression of liver metastasis.  
We observed that both secreted ITIH5 and intracellular ITIH5Δs expression in 
highly metastatic human PDAC cells is sufficient to suppress growth of both gross and 
histologic liver metastasis. This could suggest that ITIH5 suppresses the growth of PDAC 
cells within the liver, or that ITIH5 reduces the ability of disseminated cells to enter the 
liver, and thereby reduces the number of metastatic colonies. In these same experiments, 
74 
 
we did not observe any development of gross metastases in the lungs of mice with liver 
metastases. We did however observe the development of histologically apparent 
metastases in the lungs of mice injected with either control or ITIH5Δs-expressing cells. 
We do not currently know whether the absence of lung metastases in the ITIH5-
expressing cells is due to inadequate sampling, or a true difference in biology. In the lung, 
we did not observe any difference in the number or size of lung metastases between 
vector control cells and ITIH5Δs-expressing cells. This may be due to the fact that the 
lung is more easily colonized by PDAC cells than the liver [172], and so the metastasis-
suppressing effect of ITIH5 is less apparent in this tissue. Understanding the intracellular 
mechanism of PDAC metastasis suppression by ITIH5 could reveal new therapeutically 
targetable pathways that could slow the progression of disease in patients with PDAC 








 – Summary 
Here, we have explored the biology of metastasis through the role of two tumor 
suppressors, KISS1 and ITIH5, and how they suppress metastasis in the lung and the 
liver respectively. Understanding regulators of lung and liver metastasis are certainly 
relevant to metastases developing in these organs from a number of human cancers, but 
what might these data mean more broadly for research in the biology of metastasis and 
how might such data affect patients with metastatic cancer?  
For the metastasis suppressors, two main applications in humans arise in cancer 
detection and cancer treatment. With respect to cancer detection, we observed that high 
expression of ITIH5 in primary PDAC correlated with extended survival time. Surgical 
resection of primary PDAC via pancreatoduodenectomy (Krausch-Whipple procedure) 
presents several challenges for both the patient and the surgeon. For the surgeon, the 
procedure tests both the physical and mental energy of the surgeon, often requiring 
several hours due to the deep location of the pancreas, its proximity to critical vascular 
structures and variation in gastrointestinal anatomy and tumor location. For the patient, 
the pancreatoduodenectomy, commonly referred to as simply the “Whipple,” has a high 
morbidity [183], marked by long recovery times and potentially severe complications. If 
ITIH5 is a marker of patients who are likely to have increased survival after 
pancreatoduodenectomy, might then ITIH5 expression be part of a panel of biomarkers 
to stratify patients who might benefit from the procedure and spare those who are unlikely 
to benefit from it excessive morbidity?  
With respect to treatment of metastatic disease, if the mechanism of metastasis 
suppressors like ITIH5 and KISS1 could be understood, a molecular target in the pathway 
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might be revealed that could be targeted therapeutically. For example, we observed 
robust suppression of melanoma cells expressing KISS1 in vivo, but KISS1 failed to 
suppress disseminated cancer growth in the lungs grown in the PuMA ex vivo. If the factor 
responsible for this difference in KISS1 effects on cancer cell growth were discovered, 
perhaps a drug could be used to either prevent outgrowth of disseminated cancer at a 
secondary site like the lung. Understanding the biology of metastasis would be especially 
important for developing treatments for highly metastatic but mitotically indolent tumors, 
such as some neuroendocrine tumors, where conventional chemotherapies are not 
effective. In this case, targeting metastasis would provide a new treatment for a disease 
which is currently difficult to prevent further progression. Stopping spread from the 
primary before colonization of new organs or preventing cancer’s outgrowth at sites of 
dissemination could confine cancer treatment to that of a localized or chronic disease 
respectively. 
Genes guiding processes like cell proliferation, migration and resistance to cell 
death are critical for the development of multicellularity. It would seem that such genes 
are also the Achilles’ heel of multicellular organisms when they are commandeered by 
cancer as neoplastic doppelgangers.  For example, in normal physiology, KRAS regulates 
proliferation in the developing brain [184], even though KRAS is probably better known 
as one of the pillar mutations in the progression of pancreatic cancer [185]. Likewise, 
KISS1 regulates the secretion of neuropeptides in the hypothalamus [186] and ITIH5 
expression is associated with tendon development in normal physiology [187] but both of 
these genes are strong suppressors of cancer metastasis and curiously, both are 
expressed in pancreatic islets and the brain (hypothalamus and hippocampus) [29, 54, 
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65, 151, 188]. While it is not surprising that the same genes perform similar tasks in 
normal physiology and cancer (e.g. regulating proliferation), it does raise the question as 
to how cancer commandeered these genes. One possible explanation for the shared 
expression of many metastasis suppressors in both the β cells of the pancreas (e.g. 
KISS1, HMP-19, and ITIH5) and in the brain is that both the hypothalamus and β cells 
share genes which were used during evolution for both the development of the brain and 
the pancreas. While the brain and the pancreas do not share a developmental origin, they 
have converged on the use of the same genes for similar required processes like 
microvesicle assembly [189], neuropeptide release, cell adhesion [190], and 
transcriptional regulation [191]. This therefore may help explain shared gene expression 
programs between apparently different tissues [192]. 
 
Metastasis is often viewed as the pinnacle of tumor progression. Most likely, this 
is owed to the fact that many patients with the late stage cancer have metastases and 
that primary tumors which metastasize often show aggressive malignant features such 
as high proliferative indices, invasion and local recurrence. Metastasis is a hallmark of 
malignant tumors [193, 194], notwithstanding notable exceptions such as desmoid tumors 
and glioblastoma, which, while non-metastatic are undoubtedly malignant due to their 
propensity to invade locally and recur. As a rule, benign tumors do not metastasize. 
However, even this fundamental aspect of cancer biology has not gone unchallenged 
[195, 196]. Thus, it seems that while tumor progression and metastasis may coincide, the 
ability of neoplastic cells to disseminate and colonize new sites is determined by its own 
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unique biology. This biology of metastasis is not de novo, but borrowed and corrupted 
from normal physiological processes. 
Cancer is by definition a disease of multicellular organisms. That is, cells which 
“cheat” the organism by prioritizing their own survival above that of the organism exploit 
host resources [197]. As metastasis is the spread of neoplastic cells from a primary tumor 
to a secondary site and growth therein, by definition there exist several requirements of 
organisms for metastasis to occur: 1) the organisms must get cancer and therefore must 
also be multicellular 2) the organisms must have different tissues large enough to permit 
colonization of the tumor cells in a region spatially distinct from the primary tumor and 3) 
the metastatic niche must permit growth of the disseminated cells. Thus, the study of 
metastasis is generally limited to multicellular eukaryotes. While biofilms and aggregates 
do occur in Bacteria and Archea, these lack sufficient intercellular adhesion, dependency 
and differentiation to be considered a true multicellular organism. Examples of true 
multicellular differentiation and dependency do exist in Bacteria [198], but these 
aggregates lack rogue cells which independently exploit the colony in the same way 
neoplastic cells do. 
Turning to multicellular eukarotes, Volvox are a genus of algae which can 
experience a condition similar to cancer when genes which inhibit cell proliferation in 
somatic cells are not correctly expressed [199]. Volvox are comprised of a ball of cells 
differentiated into two distinct types: the majority of the cells are postmitotic, “somatic” 
flagella-containing cells on the exterior of the sphere while a smaller number of germ cells 
with the potential for proliferation exist in the center of the sphere [200]. The flagellated 
cells rely on the germ cells for regeneration and reproduction, while the germ cells rely 
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on the flagellates to move the organism to toward the light for photosynthesis and energy 
production. However, when the gene regA is not expressed in the outer somatic cells, 
they re-enter the cell cycle and resulting proliferative masses form new organisms [201]. 
In Volvox, nutrient deprivation and other environmental stresses cause the formation of 
reactive oxygen species (ROS). Sexual reproduction in Volvox has been correlated with 
increasing levels of ROS, leading to the hypothesis that sexual reproduction might 
promote survival in the face of environmental stress [202]. The same genes triggered 
during sexual reproduction of this organism are also triggered in response to wounding 
[203]. These parallel pathways of wound healing and coordinated cell proliferation are 
also seen in human cancer [204], illustrating striking parallels in biology. As yet though, 
invasion and metastasis of dysregulated Volvox cells has not been observed.   
To truly observe metastasis then, we turn to multicellular animals. One of the 
simplest phyla for which disseminated cancer has been observed is Mollusca (mollusks), 
containing bivalve species like clams and mussels [205]. In soft shell clams, primary 
gonadal tumors have been observed in the gonad region of the clam and invading 
surrounding tissues [206]. Colonization of distant organs such as the gills is apparent, but 
given the large size of the primary tumor and proximity of the tumor to the gill, it remains 
possible that this represents an extension of local invasion rather than a true metastasis. 
Models of metastasis in Drosophila have been genetically engineered by expressing 
mutant oncogenes and/or inactivating tumor suppressors. RasV12/scrib-/- flies develop 
uncontrolled proliferation of developing eye-disc epithelial cells that subsequently leave 




While the presentation of cancer may differ between species, often the genes 
regulating cancer progression and metastasis do not. So then, if we assume that genes 
selected for or against during cancer progression and metastasis have a defined role in 
normal physiology, primitive model systems with shared genetic history might provide 
valuable insight into the function and regulation of these genes, including the metastasis 
suppressors. While yet relatively unexplored, such model systems may help elucidate the 
molecular mechanism of these genes and provide a platform for pharmacologic screens 
that could be used to develop new treatments for disseminated and metastatic cancer.  
There remains a critical need for metastasis research, as disseminated disease is 
a consistent indicator of poor prognosis for patients affected by cancer. Current and future 
treatments like surgery, radiation, conventional chemotherapy and targeted therapy will 
continue to affect the growth of cancer which has spread to other regions of the body. 
Metastasis itself however, may present its own therapeutic avenue that would be effective 
at several levels. Understanding the biology of metastasis holds great potential 
scientifically and therapeutically and holds promise and hope for the current and future 
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